

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number  
**WO 2004/113379 A1**

(51) International Patent Classification?: **C07K 14/52**

(21) International Application Number:  
**PCT/GB2004/002641**

(22) International Filing Date: 21 June 2004 (21.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0314456.5 20 June 2003 (20.06.2003) GB  
10/600,790 20 June 2003 (20.06.2003) US

(71) Applicant (for all designated States except US): **ARES TRADING S.A.** [CH/CH]; Château de Vaumarcus, CH-2028 Vaumarcus (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FAGAN, Richard,**


Joseph [US/GB]; Impharmatica Limited, 60 Charlotte Street, London W1T 2NU (GB). **CHVATCHKO, Yolande** [FR/CH]; Ares Trading S.A., Château de Vaumarcus, CH-2028 Vaumarcus (CH). **GUTTERIDGE, Alex** [GB/GB]; 23 Broad Lane, Haslingfield, Cambridgeshire CB3 7JF (GB). **POWER, Christine** [GB/FR]; 10, rue des Jonquilles, F-01710 Thoiry (FR). **BOSCHERT, Ursula** [DE/CH]; Ares Trading S.A., Château de Vaumarcus, CH-2028 Vaumarcus (CH). **PHELPS, Christopher, Benjamin** [GB/GB]; Impharmatica Limited, 60 Charlotte Street, London W1T 2NU (GB).

(74) Agents: **GOODFELLOW, Hugh, Robin et al.**; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

[Continued on next page]

(54) Title: **INTERFERON GAMMA-LIKE PROTEIN**



(57) Abstract: This invention relates to a protein, termed INSP037, herein identified as an interferon gamma-like secreted protein of the four helical bundle cytokine fold, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.



GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERFERON GAMMA-LIKE PROTEIN

This invention relates to a protein, termed INSP037, herein identified as an interferon gamma-like secreted protein of the four helical bundle cytokine fold, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis,  
5 prevention and treatment of disease.

All publications, patents and patent applications cited herein are incorporated in full by reference.

### BACKGROUND

The process of drug discovery is presently undergoing a fundamental revolution as the  
10 era of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences.

15 As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

Various institutions and commercial organisations are examining sequence data as  
20 they become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

### Introduction to Secreted Proteins

25 The ability of cells to make and secrete extracellular proteins is central to many biological processes. Enzymes, growth factors, extracellular matrix proteins and signalling molecules are all secreted by cells. This is through fusion of a secretory vesicle with the plasma membrane. In most cases, but not all, proteins are directed to the endoplasmic reticulum and into secretory vesicles by a signal peptide. Signal  
30 peptides are cis-acting sequences that affect the transport of polypeptide chains from the cytoplasm to a membrane bound compartment such as a secretory vesicle.

Polypeptides that are targeted to the secretory vesicles are either secreted into the extracellular matrix or are retained in the plasma membrane. The polypeptides that are retained in the plasma membrane will have one or more transmembrane domains. Examples of secreted proteins that play a central role in the functioning of a cell are  
5 cytokines, hormones, extracellular matrix proteins (adhesion molecules), proteases, and growth and differentiation factors.

### Introduction to Cytokines

Cytokines are a family of growth factors primarily secreted from leukocytes, and are messenger proteins that act as potent regulators capable of effecting cellular processes  
10 at sub-nanomolar concentrations. Interleukins, neurotrophins, growth factors, interferons and chemokines all define cytokine families that work in conjunction with cellular receptors to regulate cell proliferation and differentiation. Their size allows cytokines to be quickly transported around the body and degraded when required. Their role in controlling a wide range of cellular functions, especially the immune  
15 response and cell growth has been revealed by extensive research over the last twenty years (Boppana, S.B (1996) Indian. J. Pediatr. 63(4):447-52). Cytokines, as for other growth factors, are differentiated from classical hormones by the fact that they are produced by a number of different cell types rather than just one specific tissue or gland, and also effect a broad range of cells via interaction with specific high affinity  
20 receptors located on target cells.

All cytokine communication systems show both pleiotropy (one messenger producing multiple effects) and redundancy (each effect is produced by more than one messenger (Tringali, G. et al (2000) Therapie. 55(1):171-5; Tessarollo, L. (1998) Cytokine Growth Factor Rev. 9(2):125-137). An individual cytokine's effects on a cell  
25 can also be dependent on its concentration, the concentration of other cytokines, the temporal sequence of cytokines, and the internal state of the cell (for example, it may be affected by the cell cycle, presence of neighbouring cells, cancerous).

Although cytokines are typically small proteins (under 200 amino acids) they are often formed from larger precursors which are post-translationally spliced. This, in  
30 addition to mRNA alternative splicing pathways, give a wide spectrum of variants of each cytokine each of which may differ substantially in biological effect. Membrane and extracellular matrix associated forms of many cytokines have also been isolated

(Okada-Ban, M. et al (2000) *Int. J. Biochem. Cell Biol.* 32(3):263-267; Atamas, S.P. (1997) *Life Sci.* 61(12):1105-1112).

Cytokines can be grouped into families, though most are unrelated. Categorisation is usually based on secondary structure composition, as sequence similarity is often very low. The families are named after the archetypal member e.g. IFN-like, IL2-like, IL1-like, IL-6 like and TNF-like (Zlotnik, A. et al., (2000) *Immunity.* 12(2):121-127).

Studies have shown cytokines are involved in many important reactions in multi-cellular organisms such as immune response regulation (Nishihira, J. (1998) *Int. J. Mol. Med.* 2(1):17-28), inflammation (Kim, P.K. et al., (2000) *Surg. Clin. North. Am.* 80(3):885-894), wound healing (Clark, R.A. (1991) *J. Cell Biochem.* 46(1):1-2), embryogenesis and development, and apoptosis (Flad, H.D. et al., (1999) *Pathobiology.* 67(5-6):291-293). Pathogenic organisms (both viral and bacterial) such as HIV and Kaposi's sarcoma-associated virus encode anti-cytokine factors as well as cytokine analogues, which allow them to interact with cytokine receptors and control the body's immune response (Sozzani, S. et al., (2000) *Pharm. Acta. Helv.* 74(2-3):305-312; Aoki, Y. et al., (2000) *J. Hematother. Stem Cell Res.* 9(2):137-145). Virally encoded cytokines, virokines, have been shown to be required for pathogenicity of viruses due to their ability to mimic and subvert the host immune system.

Cytokines may be useful for the treatment, prevention and/or diagnosis of a wide variety of medical conditions and diseases, including immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related complex, neurological

disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection.

Clinical use of cytokines has focused on their role as regulators of the immune system (Rodriguez, F.H. et al., (2000) *Curr. Pharm. Des.* 6(6):665-680) for instance in  
5 promoting a response against thyroid cancer (Schmutzler, C. et al., (2000) 143(1):15-24). Their control of cell growth and differentiation has also made cytokines anti-cancer targets (Lazar-Molnar, E. et al., (2000) *Cytokine*. 12(6):547-554; Gado, K. (2000) 24(4):195-209). Novel mutations in cytokines and cytokine receptors have been shown to confer disease resistance in some cases (van Deventer, S.J. et al.,  
10 (2000) *Intensive Care Med.* 26 (Suppl 1):S98:S102). The creation of synthetic cytokines (muteins) in order to modulate activity and remove potential side effects has also been an important avenue of research (Shanafelt, A.B. et al., (1998) 95(16):9454-9458).

Thus, cytokine molecules have been shown to play a role in diverse physiological  
15 functions, many of which can play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and as such identification of novel cytokine molecules is highly relevant as they may play a role in or be useful in the development of treatments for the diseases identified above, as well as other disease states.

## 20 **Introduction to Interferons**

Interferons are members of the four-helical bundle family of cytokines. They are classified as Type I or Type II depending on their structure and their stability in acid medium. Type I interferons are classified into five groups on the basis of their  
25 sequence: interferon-alpha (IFN- $\alpha$ ), interferon-beta (IFN- $\beta$ ), interferon-omega (IFN- $\theta$ ) and interferon-tau (IFN- $\tau$ ). The only Type II interferon so far identified is interferon-gamma (IFN- $\gamma$ ) which is produced by activated T cells and NK cells.

The genes for Type I interferons are clustered on human chromosome 9. In humans, it is estimated that there are at least 14 IFN- $\alpha$  non-allelic genes and the number of naturally-occurring IFN- $\alpha$  proteins is increased further by allelic forms of IFN- $\alpha$   
30 genes (Jussain *et al*, 1996, *J. Interferon Cytokine Res* 16: 853-9).

Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface, so initiating a complex sequence of intracellular events. Type I interferons induce a wide variety of biological responses which include antiviral, immunomodulatory and anti-proliferative effects and, as a result of these effects, they have proved to be effective in the treatment of diverse diseases and conditions.

Interferons are potent antiviral agents and alpha-interferons, in particular, have been found to be useful in the treatment of a variety of viral infections including human papillomavirus infection, Hepatitis B and Hepatitis C infections (Jaeckel *et al*, 2001, 345(2): 1452-7). Type I interferons also inhibit cellular proliferation and alpha-interferons have been used clinically for many years in the treatment of a variety of malignancies including hairy cell leukaemia, multiple myeloma, chronic lymphocytic leukaemia, low-grade lymphoma, Kaposi's sarcoma, chronic myelogenous leukaemia, renal-cell carcinoma, and ovarian cancer. In addition, type I interferons are useful in treating autoimmune diseases, with interferon-beta having been approved for the treatment of multiple sclerosis.

Interferon-tau was initially identified in conceptus homogenates in ruminants although it has since been identified in humans (see WO96/35789). Although interferon-tau displays many similar activities to other Type-I interferons, it also displays some different effects. In particular, it has an anti-luteolytic effect which promotes the establishment and maintenance of pregnancy (Martal *et al*, *Reprod. Fertil Dev.*, 1997, 9(3): 355-80). In addition, whilst viral induction of interferon-alpha and interferon-beta is transient, lasting a few hours, viral induction of interferon-tau expression can last several days and has been found to have antiretroviral effects against HIV-1 (Dereuddre-Bosquet *et al*, *J. Acquir. Immune Defic Syndr. Hum. Retrovirol*, 1996, 11(3): 241-6).

Type II interferons (including interferon gamma) may be useful for the treatment, prevention and/or diagnosis of medical conditions and diseases which include immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myasthenia gravis, Guillain-Barré syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis (Kimball *et al*, *Arch Dermatol* 2002 Oct;138(10):1341-6) and graft-versus-host disease (Miura Y., *et al*, *Blood* 2002 Oct 1;100(7):2650-8), monocyte and

neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease (Anaya et al., J Rheumatol 2002 Sep; 29(9):1874-6), Crohn's disease (Schmit A. et al., Eur Cytokine Netw 2002 Jul-Sep;13(3):298-305), ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease (Oei J et al., Acta Paediatr 2002;91(11):1194-9), aggressive and chronic periodontitis (Gonzales JR, et al., J clin Periodontol 2002 Sep;29(9):816-22), cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas (Vaishampayan U, Clin Cancer Res 2002 Dec;8(12):3696-701), mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis (Semin Liver Dis 2002;22 Suppl 1:7), AIDS (Dereuddre-Bosquet N., et al., J Acquir Immune Defic Syndr Hum Retroviol 1996 Mar 1; 11(3):241-6), AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity (Bogdan, Current Opinion in Immunology 2000, 12:419-424), Peyronie's disease (Lacy et al., Int J Impot Res 2002 Oct;14(5):336-9), tuberculosis (Dieli et al., J Infect Dis 2002 Dec 15;186(12):1835-9), and viral infection (Pfeffer LM, Semin Oncol 1997 Jun 24;S9-63-69).

In summary, secreted proteins that are members of the four helical bundle cytokine family have been shown to play a role in diverse physiological functions, many of which can play a role in disease processes. In particular, interferons have been found to play an



important role in a variety of physiological processes and as a result, have proved to be useful in the treatment of a wide range of diseases. However, there remains a need for the identification of novel interferons to enable new drugs to be developed for the treatment and prevention of disease, including those diseases mentioned above.

## 5 THE INVENTION

The invention is based on the discovery that the INSP037 protein is an interferon gamma-like secreted protein of the four helical bundle cytokine fold.

In one embodiment of the first aspect of the invention, there is provided a polypeptide, which polypeptide:

- 10 (i) comprises the amino acid sequence as recited in SEQ ID NO:2;
- (ii) is a fragment thereof that is an interferon gamma-like secreted protein of the four helical bundle cytokine fold, or having an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

15 According to a second embodiment of this first aspect of the invention, there is provided a polypeptide which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:2;
- (ii) is a fragment thereof that is an interferon gamma-like secreted protein of the four helical bundle cytokine fold, or having an antigenic determinant in  
20 common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as "the INSP037 polypeptide". INSP037 is also referred to herein as IPAAA44548.

Preferably, the INSP037 polypeptides according to the first aspect of the invention  
25 function as an interferon gamma-like secreted protein of the four helical bundle cytokine fold. The term "interferon gamma-like secreted protein of the four helical bundle cytokine fold" will be understood by the skilled person, who will readily be able to ascertain whether a polypeptide functions as a member of this class using one of a variety of assays known in the art. The presence of a four helical bundle cytokine  
30 fold may be identified by an analysis of protein sequence and secondary structure.

Interferon activity is often measured as an anti-viral activity or antiproliferative activity on cancer cells. Examples of assays may be found in Schiller J.H., J Interferon Res 1986; 6(6):615-25, Gibson, U.E. *et al.*, J Immunol Methods (1989) 20; 125(1-2):105-13 and Chang *et al.*, J. Biol. Chem. (2002) 277(9):7118-7126.

- 5 In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention.

Preferably, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSP037 polypeptide). Preferably, the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ  
10 ID NO:1 (encoding the INSP037 polypeptide) or is a redundant equivalent or fragment of this sequence.

In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

- 15 In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention. Examples of such vectors include pDEST14-IPAAA44548-6HIS (see Figure 10), PCR11-TOPO-IPAAA44548 (see Figure 11), pDEST14-IPAAA44548-6HIS (see Figure 12) and pEAK12D-IPAAA44548-6HIS (see Figure 13).

- 20 In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

In a sixth aspect, the invention provides a ligand which binds specifically to, and which preferably inhibits the secreted protein activity, more preferably inhibits the interferon gamma-like activity of a polypeptide of the first aspect of the invention.

- 25 In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

A compound of the seventh aspect of the invention may either increase (agonise) or  
30 decrease (antagonise) the level of expression of the gene or the activity of the polypeptide.

Importantly, the identification of the function of the INSP037 polypeptide allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease. Ligands and compounds according to the sixth and seventh aspects of the invention may be identified using such methods.

- 5 These methods are included as aspects of the present invention. Using these methods, it will now be possible to identify inhibitors or antagonists of INSP037, such as, for example, monoclonal antibodies, which may be of use in modulating INSP037 activity in vivo in clinical applications. Such compounds are likely to be useful in counteracting the IFN $\gamma$ -like activity of the INSP037 polypeptides.
- 10 In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis of diseases in which
- 15 interferons are implicated, particularly IFN- $\gamma$ -like polypeptides. Such diseases include, but are not limited to, immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myasthenia gravis, Guillain-Barré syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis (Kimball et al., Arch Dermatol 2002
- 20 Oct:138(10):1341-6) and graft-versus-host disease (Miura Y., et al., Blood 2002 Oct 1:100(7):2650-8), monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease (Anaya et al., J Rheumatol 2002 Sep; 29(9):1874-6),
- 25 Crohn's disease (Schmit A. et al., Eur Cytokine Netw 2002 Jul-Sep:13(3):298-305), ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive
- 30 pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease (Oei J et al., Acta Paediatr 2002:91(11):1194-9), aggressive and chronic periodontitis (Gonzales JR, et al., J clin Periodontol 2002

Sep:29(9):816-22), cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas (Vaishampayan U, Clin Cancer Res 2002 Dec:8(12):3696-701), mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis (Semin Liver Dis 2002:22 Suppl 1:7), AIDS (Dereuddre-Bosquet N., et al., J Acquir Immune Defic Syndr Hum Retroviol 1996 Mar 1: 11(3):241-6), AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity (Bogdan, Current Opinion in Immunology 2000, 12:419-424), Peyronie's disease (Lacy et al., Int J Impot Res 2002 Oct:14(5):336-9), tuberculosis (Dieli et al., J Infect Dis 2002 Dec 15;186(12):1835-9), and viral infection (Pfeffer LM, Semin Oncol 1997 Jun 24:S9-63-69).

These moieties of the first, second, third, fourth, fifth, sixth or seventh aspect of the invention may also be used in the manufacture of a medicament for the treatment of such diseases.

In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out *in vitro*. Similar methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease.

A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect

of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid  
5 hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

10 Preferably, the disease diagnosed by a method of the ninth aspect of the invention is a disease in which interferons are implicated, as described above.

In a tenth aspect, the invention provides for the use of the polypeptide of the first aspect of the invention as an interferon gamma-like secreted protein of the four helical bundle cytokine fold. One suitable use of INSP037 is use as an adjuvant in bacterial,  
15 fungal or viral infections, in conjunction with well-established treatments. Other potential uses include use of INSP037 to activate macrophages, and to increase expression of MHC molecules and antigen processing components. Experimental results included herein confirm the predicted IFN $\gamma$ -like activity of INSP037. This discovery opens a series of interesting therapeutic applications for the protein *per se*,  
20 in that the polypeptides of the invention can be tested for suitability for use in known applications of IFN $\gamma$ , such as in anti-cancer applications (see, for example, Vaishampayan U, Clin Cancer Res 2002 Dec;8(12):3696-701). It will also now be possible to identify inhibitors or antagonists of INSP037, such as, for example, monoclonal antibodies, which may be of use in further studies of INSP037 activity *in vivo* or in clinical applications.  
25

In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the  
30 sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.

In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound  
5 of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease in which interferons are implicated. Such diseases include those described above in connection with the eighth aspect of the invention.

In a thirteenth aspect, the invention provides a method of treating a disease in a  
10 patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention.

15 For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, host cell, ligand or compound administered to the patient should be an agonist.  
20 Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, host cell, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes  
25 and ligands, such as antibodies.

Preferably, the disease is a disease in which interferons are implicated, as described above.

In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a  
30 polypeptide of the first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such

a disease.

Preferably, the disease is a disease in which interferons are implicated, as described above.

A summary of standard techniques and procedures which may be employed in order to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of the appended claims.

Standard abbreviations for nucleotides and amino acids are used in this specification.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art.

Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986).

As used herein, the term "polypeptide" includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins).

The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is employed for purification of the mature polypeptide sequence.

The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.



The modifications that occur in a polypeptide often will be a function of how the polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell.

The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods.

The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the INSP037 polypeptides. Two polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Preferably, percentage identity, as referred to herein, is as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; <http://www.ncbi.nlm.nih.gov/>) [Blosum 62 matrix; gap open penalty=11 and gap extension penalty=1].

Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid

substitutions, insertions or deletions) of the INSP037 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded  
5 by the genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any  
10 combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions.

Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group.

15 Typically, greater than 80% identity between two polypeptides is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the INSP037 polypeptide, or with active fragments thereof, of greater than 80%. More preferred polypeptides have degrees of identity of greater than 90%, 95%, 98% or  
20 99%, respectively.

The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome Threader technology that forms one aspect of the search tools used to generate the Biopendium search database may  
25 be used (see PCT application published as WO 01/69507) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the INSP037 polypeptides, are predicted to be interferon gamma-like secreted proteins of the four helical bundle cytokine fold by virtue of sharing significant structural homology with the INSP037 polypeptide sequences. By "significant  
30 structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty of 10% and above.

The polypeptides of the first aspect of the invention also include fragments of the

INSP037 polypeptides and fragments of the functional equivalents of these polypeptides, provided that those fragments retain interferon gamma-like activity, or have an antigenic determinant in common with these polypeptides.

As used herein, the term "fragment" refers to a polypeptide having an amino acid  
5 sequence that is the same as part, but not all, of the amino acid sequence of INSP037 polypeptides or one of its functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

10 Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre- and/or pro- polypeptide  
15 region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide.

The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such  
20 as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

25 The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub> and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind  
30 to the polypeptides of the first aspect of the invention.

By "substantially greater affinity" we mean that there is a measurable increase in the affinity for a polypeptide of the invention as compared with the affinity for known

cell-surface receptors.

Preferably, the affinity is at least 1.5-fold, 2-fold, 5-fold 10-fold, 100-fold,  $10^3$ -fold,  $10^4$ -fold,  $10^5$ -fold,  $10^6$ -fold or greater for a polypeptide of the invention than for known IFN $\gamma$ -like polypeptides.

- 5 If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides  
10 may be chemically coupled include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

- Monoclonal antibodies to the polypeptides of the first aspect of the invention can also  
15 be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985).

- 20 Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance  
25 by PCR techniques known in the art, and cloned and expressed in appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, 84, 3439 (1987)), may also be of use.

- The antibody may be modified to make it less immunogenic in an individual, for  
30 example by humanisation (see Jones *et al.*, *Nature*, 321, 522 (1986); Verhoeven *et al.*, *Science*, 239, 1534 (1988); Kabat *et al.*, *J. Immunol.*, 147, 1709 (1991); Queen *et al.*, *Proc. Natl. Acad. Sci. USA*, 86, 10029 (1989); Gorman *et al.*, *Proc. Natl. Acad. Sci.*

USA, 88, 34181 (1991); and Hodgson *et al.*, Bio/Technology, 9, 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen-binding domains, each domain being directed against a different epitope.

- 10 Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. *et al.*, (1990), Nature 348, 552-554; Marks, J. *et al.*, (1992) Biotechnology 10, 779-783).
- 15 The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. *et al.*, (1991) Nature 352, 624-628).

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequences as recited in SEQ ID NO:2 and functionally equivalent polypeptides. These nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).

The nucleic acid molecules of the invention also include sequences that are complementary to nucleic acid molecules described above (for example, for antisense or probing purposes).

Nucleic acid molecules of the present invention may be in the form of RNA, such as

mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase  
5 phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the *in vitro* or *in vivo* transcription of DNA sequences.

The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be  
10 the non-coding strand, also referred to as the anti-sense strand.

The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide  
15 backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. *et al.* (1993) *Anticancer Drug Des.* 8:53-63).

20 A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:2 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:1. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes a polypeptide of SEQ ID NO:2. Such nucleic acid molecules may include, but are not limited to, the coding sequence for the mature  
25 polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with further additional, non-coding sequences, including non-coding 5' and 3'  
30 sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also include additional sequences which encode additional amino acids, such as those which provide additional functionalities.

The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of the first aspect of the invention. Such a nucleic acid molecule may be a naturally-occurring variant such as a naturally-occurring allelic variant, or the molecule may be  
5 a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions,  
10 deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions.

The nucleic acid molecules of the invention can also be engineered, using methods  
15 generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction  
20 sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth.

Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within  
25 the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and  
30 the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.

The nucleic acid molecules of the invention also include antisense molecules that are

partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee *et al.*, Nucleic Acids Res 6, 3073 (1979); Cooney *et al.*, Science 241, 456 (1988); Dervan *et al.*, Science 251, 1360 (1991).

The term "hybridization" as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook *et al.* [supra]).

The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook *et al* [supra]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

"Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by



washing the filters in 0.1X SSC at approximately 65°C. Low stringency conditions involve the hybridisation reaction being carried out at 35°C (see Sambrook *et al.* [supra]). Preferably, the conditions used for hybridization are those of high stringency.

- 5 Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the INSP037 polypeptide (SEQ ID NO:2) and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at  
10 least 80% identical over its entire length to the nucleic acid molecules having the sequence produced by SEQ ID NO:1 or a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic  
15 acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSP037 polypeptides.

The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes;  
20 and (b) detecting any such duplexes that are formed.

As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the INSP037 polypeptides and to isolate  
25 cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and  
30 may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase

(Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the  
5 Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INSP037 polypeptides is to probe a genomic or  
10 cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel *et al.* (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are  
15 complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1) are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the  
20 ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

In many cases, isolated cDNA sequences will be incomplete, in that the region  
25 encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method  
30 of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman *et al.*, PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the Marathon<sup>TM</sup> technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly

different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T. *et al.* (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. *et al.* (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of Parker, J.D. *et al.* (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder<sup>TM</sup> libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationships between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any

sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

- 5 The nucleic acid molecules of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the polypeptide in tissues by detection of the mRNAs that encode them. These techniques include *in situ* hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of
- 10 the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature.

- Gene silencing approaches may also be undertaken to down-regulate endogenous
- 15 expression of a gene encoding a polypeptide of the invention. RNA interference (RNAi) (Elbashir, SM *et al.*, Nature 2001, 411, 494-498) is one method of sequence specific post-transcriptional gene silencing that may be employed. Short dsRNA oligonucleotides are synthesised *in vitro* and introduced into a cell. The sequence specific binding of these dsRNA oligonucleotides triggers the degradation of target
- 20 mRNA, reducing or ablating target protein expression.

Efficacy of the gene silencing approaches assessed above may be assessed through the measurement of polypeptide expression (for example, by Western blotting), and at the RNA level using TaqMan-based methodologies.

- The vectors of the present invention comprise nucleic acid molecules of the invention
- 25 and may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic.

- The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host
- 30 cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook *et al* (supra) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press,

San Diego, London, Boston, New York, Sydney, Tokyo, Toronto).

Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of  
5 a variety of well-known and routine techniques, such as, for example, those described in Sambrook *et al.*, (supra). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell.

10 Examples of suitable expression systems include, for example, chromosomal, episomal and virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and  
15 retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid.

Particularly suitable expression systems include microorganisms such as bacteria  
20 transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for  
25 example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention.

Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986)  
30 and Sambrook *et al.*, [supra]. Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading,

ballistic introduction or infection (see Sambrook *et al.*, 1989 [supra]; Ausubel *et al.*, 1991 [supra]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the system.

- 5 The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- 10 Leader sequences can be removed by the bacterial host in post-translational processing.

In addition to control sequences, it may be desirable to add regulatory sequences that allow for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a

15 gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers, promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory

20 sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSport1<sup>TM</sup> plasmid (Gibco BRL)

25 and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are

30 preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

An expression vector is constructed so that the particular nucleic acid coding

sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at  
5 the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.

The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding  
10 sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.

For long-term, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of  
15 replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully  
20 express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO),  
25 HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines.

In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA (the  
30 "MaxBac" kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Particularly suitable host cells for use in this system include

insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells.

There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those described in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 5 30, 3861-3863 (1991).

In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the transferred gene. Practically all plants can be regenerated from cultured 10 cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

Examples of particularly preferred bacterial host cells include *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells.

Examples of particularly suitable host cells for fungal expression include yeast cells 15 (for example, *S. cerevisiae*) and *Aspergillus* cells.

Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. *et al.* (1980) *Cell* 22:817-23) genes that can be employed in tk- or aprt± 20 cells, respectively.

Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. *et al.* (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. 25 *et al* (1981) *J. Mol. Biol.* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art.

Although the presence or absence of marker gene expression suggests that the gene of 30 interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the



absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

- 5 Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques  
10 (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. *et al.* (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. *et al.* (1983) J. Exp. Med, 158, 1211-1216).
- 15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled  
20 polynucleotide. Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using  
25 a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH)).

Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

- 30 Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of

somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention.

The polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification.

Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. *et al.* (1992), *Prot. Exp. Purif.* 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. *et al.* (1993; *DNA Cell Biol.* 12:441-453).

If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be secreted into the culture medium of the host cell in which it is expressed. In this event, the polypeptides of the invention may be purified from the culture medium may be harvested prior to use in the screening assay, for example

using standard protein purification techniques such as gel exclusion chromatography, ion-exchange chromatography or affinity chromatography. Examples of suitable methods of protein purification are provided in the Examples herein. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Alternatively, it may be preferred that the polypeptides of the invention be expressed as cell-surface fusion proteins. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACs) or immunoaffinity techniques.

The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991).

Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented.

The polypeptide of the invention that is employed in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test

compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by  
5 activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.

A preferred method for identifying a ligand for the IFN $\gamma$ -like polypeptides of the present invention comprises:

- 10 (a) contacting a cell expressing on the surface thereof a putative binding partner for a IFN-like polypeptide of the invention, the putative binding partner being capable of providing a detectable signal in response to the binding of a polypeptide of the present invention, (or associated with a second component capable of providing a detectable signal in response to the binding of a  
15 polypeptide of the present invention), to the putative binding partner, with a polypeptide of the present invention to be screened under conditions to permit binding to the putative binding partner; and
- (b) determining whether the polypeptide of the present invention binds to and activates or inhibits the putative binding partner by measuring the level of a  
20 signal generated from the interaction of the polypeptide of the present invention with the putative binding partner.

A further preferred method for identifying a ligand for the IFN $\gamma$ -like polypeptides of the present invention comprises:

- 25 (a) contacting a cell expressing on the surface thereof a putative binding partner for a IFN $\gamma$ -like polypeptide of the invention, the putative binding partner being capable of providing a detectable signal in response to the binding of a polypeptide of the present invention, (or associated with a second component capable of providing a detectable signal in response to the binding of a polypeptide of the present invention), to the putative binding partner, with a  
30 polypeptide of the present invention to permit binding to the putative binding partner; and
- (b) determining whether the polypeptide of the present invention binds to and

activates or inhibits the putative binding partner by comparing the level of a signal generated from the interaction of the polypeptide of the present invention with the putative binding partner with the level of a signal in the absence of the polypeptide of the present invention.

- 5 In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of labelled or unlabelled INSP037 polypeptides.

In another embodiment of the method for identifying an agonist or antagonist of a polypeptide of the present invention comprises:

- 10 determining the inhibition of binding of a polypeptide of the present invention to cells which have a ligand expressed at the surface thereof, or to cell membranes containing such a ligand, in the presence of a candidate compound under conditions to permit polypeptide binding to the ligand, and determining the amount of polypeptide bound to the ligand. A compound capable of causing reduction of binding of a polypeptide  
15 of the present invention is considered to be an agonist or antagonist. Preferably the polypeptide of the invention is labelled.

More particularly, a method of screening for an antagonist or agonist compound comprises the steps of:

- (a) incubating a labelled polypeptide of the present invention with a whole cell  
20 expressing a ligand according to the invention on the cell surface, or a cell membrane containing a ligand of the invention,
- (b) measuring the amount of labelled polypeptide bound to the whole cell or the cell membrane;
- (c) adding a candidate compound to a mixture of labelled polypeptide and the  
25 whole cell or the cell membrane of step (a) and allowing the mixture to attain equilibrium;
- (d) measuring the amount of labelled polypeptide bound to the whole cell or the cell membrane after step (c); and
- (e) comparing the difference in the labelled polypeptide bound in step (b) and (d),  
30 such that the compound which causes the reduction in binding in step (d) is considered to be an agonist or antagonist.

The polypeptides may be found to modulate a variety of physiological and pathological processes in a dose-dependent manner in the above-described assays. Thus, the “functional equivalents” of the polypeptides of the invention include polypeptides that exhibit any of the same modulatory activities in the above-described  
5 assays in a dose-dependent manner. Although the degree of dose-dependent activity need not be identical to that of the polypeptides of the invention, preferably the “functional equivalents” will exhibit substantially similar dose-dependence in a given activity assay compared to the polypeptides of the invention.

Alternatively, simple binding assays may be used, in which the adherence of a test  
10 compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner,  
15 the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.

Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using  
20 monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured.

Assay methods that are also included within the terms of the present invention are those that involve the use of the genes and polypeptides of the invention in overexpression or ablation assays. Such assays involve the manipulation of levels of these genes/polypeptides in cells and assessment of the impact of this manipulation event on the physiology of the manipulated cells. For example, such experiments  
25 reveal details of signalling and metabolic pathways in which the particular genes/polypeptides are implicated, generate information regarding the identities of polypeptides with which the studied polypeptides interact and provide clues as to methods by which related genes and proteins are regulated.  
30

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid  
5 substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

10 The polypeptide of the invention may be used to identify membrane-bound or soluble receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative  
15 receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance (supplied by Biacore AB, Uppsala, Sweden) and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of the  
20 polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above.

25 The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable  
30 pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight.

The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts



such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

- 5 Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

- The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, 15 intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

- Direct delivery of the compositions will generally be accomplished by injection, 25 subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

- If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a 30 pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes,

receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

- 5 In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

In an alternative approach, expression of the gene encoding the polypeptide can be  
10 inhibited using expression blocking techniques, such as the use of antisense nucleic acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns)  
15 of the gene encoding the polypeptide. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. *et al.*  
20 (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated *in situ* from expression *in vivo*.

- 25 In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the  
30 mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and

may contain modified bases.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised by endogenous endonucleases.

For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition. Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide.

Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

Gene therapy of the present invention can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, *in vivo* gene therapy does not require isolation and purification of a patient's cells.

The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of

the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles  
5 containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo* (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

- 10 Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

- 15 Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies  
20 harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

- Since polypeptides may be broken down in the stomach, vaccines comprising  
25 polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous  
30 sterile suspensions which may include suspending agents or thickening agents.

The vaccine formulations of the invention may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials and may be stored in a

freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Genetic delivery of antibodies that bind to polypeptides according to the invention  
5 may also be effected, for example, as described in International patent application WO98/55607.

The technology referred to as jet injection (see, for example, [www.powderject.com](http://www.powderject.com)) may also be useful in the formulation of vaccine compositions.

A number of suitable methods for vaccination and vaccine delivery systems are  
10 described in International patent application WO00/29428.

This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a  
15 disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may  
20 be used directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki *et al.*, *Nature*, 324, 163-166 (1986); Bej, *et al.*, *Crit. Rev. Biochem. Molec. Biol.*, 26, 301-334 (1991); Birkenmeyer *et al.*, *J. Virol. Meth.*, 35, 117-126 (1991); Van Brunt, J., *Bio/Technology*, 8, 291-294 (1990)) prior  
25 to analysis.

In one embodiment, this aspect of the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is  
30 indicative of disease. The method may comprise the steps of:

a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a

nucleic acid molecule of the invention and the probe;

b) contacting a control sample with said probe under the same conditions used in step a);

c) and detecting the presence of hybrid complexes in said samples;

5 wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

A further aspect of the invention comprises a diagnostic method comprising the steps of:

a) obtaining a tissue sample from a patient being tested for disease;

10 b) isolating a nucleic acid molecule according to the invention from said tissue sample; and

c) diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease.

To aid the detection of nucleic acid molecules in the above-described methods, an  
15 amplification step, for example using PCR, may be included.

Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be  
20 distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid  
25 probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

Such diagnostics are particularly useful for prenatal and even neonatal testing.

30 Point mutations and other sequence differences between the reference gene and

"mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita *et al.*, Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.

DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (for example, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).

In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by *in situ* analysis (see, for example, Keller *et al.*, DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence *in situ* hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck *et al.*, Science, 250, 559-562 (1990), and Trask *et al.*, Trends, Genet., 7, 149-154 (1991)).

In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science

(1996), Vol 274, pp 610-613).

In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee *et al*); Lockhart, D. J. *et al.* (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. *et al.* (1996) Proc. Natl. Acad. Sci. 93: 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al*). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

Assay techniques that can be used to determine levels of a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.



Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably humans, with antibody to the polypeptide under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, such as by photometric means.

Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several of which are described above.

Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.

A diagnostic kit of the present invention may comprise:

- (a) a nucleic acid molecule of the present invention;
- (b) a polypeptide of the present invention; or
- (c) a ligand of the present invention.

In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a

nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA.

- 5 In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention.

To detect polypeptides according to the invention, a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention; and a reagent  
10 useful for the detection of a binding reaction between the antibody and the polypeptide.

Such kits will be of use in diagnosing a disease or susceptibility to disease, particularly immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis,  
15 myasthenia gravis, Guillain-Barré syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis (Kimball et al., Arch Dermatol 2002 Oct:138(10):1341-6) and graft-versus-host disease (Miura Y., et al., Blood 2002 Oct 1:100(7):2650-8), monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's  
20 disease (Anaya et al., J Rheumatol 2002 Sep; 29(9):1874-6), Crohn's disease (Schmit A. et al., Eur Cytokine Netw 2002 Jul-Sep:13(3):298-305), ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing  
25 spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease (Oei J et al., Acta Paediatr 2002:91(11):1194-9), aggressive and chronic  
30 periodontitis (Gonzales JR, et al., J clin Periodontol 2002 Sep:29(9):816-22), cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas (Vaishampayan U, Clin Cancer

Res 2002 Dec:8(12):3696-701), mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis (Semin Liver Dis 2002:22 Suppl 1:7), AIDS (Dereuddre-Bosquet N., et al., J Acquir Immune Defic Syndr Hum Retroviol 1996 Mar 1: 11(3):241-6), AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity (Bogdan, Current Opinion in Immunology 2000, 12:419-424), Peyronie's disease (Lacy et al., Int J Impot Res 2002 Oct:14(5):336-9), tuberculosis (Dieli et al., J Infect Dis 2002 Dec 15;186(12):1835-9), and viral infection (Pfeffer LM, Semin Oncol 1997 Jun 24:S9-63-69).

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to INSP037 polypeptides.

It will be appreciated that modification of detail may be made without departing from the scope of the invention.

## 20 **Brief description of the Figures**

**Figure 1:** Results from Inpharmatica Genome Threader query using SEQ ID NO:2.

**Figure 2:** Alignment generated by Inpharmatica Genome Threader between SEQ ID NO:2 and closest related structure.

**Figure 3:** INSP037 predicted nucleotide sequence (comprising SEQ ID NO:1) with translation (SEQ ID NO:2).

**Figure 4:** INSP037 cloned nucleotide sequence (comprising SEQ ID NO:1) with translation (SEQ ID NO:2), demonstrating that the predicted and cloned sequence for INSP037 are identical.

**Figure 5:** Map of PCRII-TOPO-IPAAA44548.

**Figure 6:** Map of expression vector pEAK12d.

**Figure 7:** Map of plasmid pDONR201.

**Figure 8:** Map of expression vector pEAK12d-IPAAA44548-6HIS.

**Figure 9:** Map of *E. coli* expression vector pDEST14.

**Figure 10:** Map of plasmid pDEST14-IPAAA44548-6HIS.

**Figure 11:** Nucleotide sequence of PCRII-TOPO-IPAAA44548.

5 **Figure 12:** Nucleotide sequence of pDEST14-IPAAA44548-6HIS.

**Figure 13:** Nucleotide sequence of pEAK12D-IPAAA44548-6HIS.

**Figure 14:** The NCBI-NR results for INSP037 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSP037 to be novel.

10 **Figure 15:** The NCBI-month-aa results for INSP037 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSP037 to be novel.

**Figure 16A:** The translated nucleotide database NCBI-month-nt results for INSP037 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSP037 to be novel.

**Figure 16B:** The NCBI-nt results for INSP037 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSP037 to be novel.

15 **Figure 17:** Results of an investigation of INSP037 activity in a murine model of ConA-induced fulminant hepatitis.

**Figure 18:** Positive control showing effects of IL-6 upon a murine model of ConA-induced fulminant hepatitis.

## Examples

20 Example 1: Identification of INSP037

The polypeptide sequence derived from SEQ ID NO:2 which represents the translation of exons from INSP037 was used as a query in the Inpharmatica Genome Threader tool against protein structures present in the PDB database. The top match is the structure of a four helical bundle cytokine family member. The top match aligns to  
25 the query sequence with a Genome Threader confidence of 84% (Figure 1). Figure 2 shows the alignment of the INSP037 query sequence to the sequence of Bovine interferon-gamma (PDB-1d9g) a member of the four helical bundle cytokine family (Randal *et al* Acta Crystallogr D Biol Crystallogr. 2000 Jan;56 (Pt 1):14-24). Note that the INSP037 polypeptide sequence is referred to as "IPAAA445" in Figure 2.

Members of the four helical bundle cytokine family of proteins are of therapeutic importance.

Figure 16B shows that INSP037 can be found on *Homo sapiens* chromosome 3. As described above, all Type I interferons are clustered on chromosome 9. Therefore, the  
 5 location of the INSP037 gene on chromosome 3 (3q25.33, chr3:157121275-157121511 (on hg15/build 33)) is in accordance with its annotation herein as an IFN-gamma like interferon, and thus as a Type II interferon.

Example 2: Cloning of INSP037 (IPAAA44548) from cDNA libraries

cDNA libraries

10 Human cDNA libraries (in bacteriophage lambda ( $\lambda$ ) vectors) were purchased from Stratagene or Clontech or prepared at the Serono Pharmaceutical Research Institute in  $\lambda$  ZAP or  $\lambda$  GT10 vectors according to the manufacturer's protocol (Stratagene). Bacteriophage  $\lambda$  DNA was prepared from small scale cultures of infected *E.coli* host strain using the Wizard Lambda Preps DNA purification system according to the  
 15 manufacturer's instructions (Promega, Corporation, Madison WI.) The list of libraries and host strains used is shown in Table 1.

**Table 1: Human cDNA libraries**

Library	Tissue/cell source	Vector	Host strain	Supplier	Cat. no.
1	human fetal brain	Zap II	XL1-Blue MRF'	Stratagene	936206
2	human ovary	GT10	LE392	Clontech	HL1098a
3	human pituitary	GT10	LE392	Clontech	HL1097a
4	human placenta	GT11	LE392	Clontech	HL1075b
5	human testis	GT11	LE392	Clontech	HL1010b
6	human sustanta nigra	GT10	LE392	in house	
7	human fetal brain	GT10	LE392	in house	
8	human cortex brain	GT10	LE392	in house	
9	human colon	GT10	LE392	Clontech	HL1034a
10	human fetal brain	GT10	LE392	Clontech	HL1065a
11	human fetal lung	GT10	LE392	Clontech	HL1072a

12	human fetal kidney	GT10	LE392	Clontech	HL1071a
13	human fetal liver	GT10	LE392	Clontech	HL1064a
14	human bone marrow	GT10	LE392	Clontech	HL1058a
15	human peripheral blood monocytes	GT10	LE392	Clontech	HL1050a
16	human placenta	GT10	LE392	in house	
17	human SHSYSY	GT10	LE392	in house	
18	human U373 cell line	GT10	LE392	in house	
19	human CFPoc-1 cell line	Uni Zap	XL1-Blue MRF'	Stratagene	936206
20	human retina	GT10	LE392	Clontech	HL1132a
21	human urinary bladder	GT10	LE392	in house	
22	human platelets	Uni Zap	XL1-Blue MRF'	in house	
23	human neuroblastoma Kan + TS	GT10	LE392	in house	
24	human bronchial smooth muscle	GT10	LE392	in house	
25	human bronchial smooth muscle	GT10	LE392	in house	
26	human Thymus	GT10	LE392	Clontech	HL1127a
27	human spleen 5' stretch	GT11	LE392	Clontech	HL1134b
28	human peripheral blood monocytes	GT10	LE392	Clontech	HL1050a
29	human testis	GT10	LE392	Clontech	HL1065a
30	human fetal brain	GT10	LE392	Clontech	HL1065a
31	human substantia Nigra	GT10	LE392	Clontech	HL1093a
32	human placenta#11	GT11	LE392	Clontech	HL1075b
33	human Fetal brain	GT10	LE392	Clontech	custom
34	human placenta #59	GT10	LE392	Clontech	HL5014a
35	human pituitary	GT10	LE392	Clontech	HL1097a
36	human pancreas #63	Uni Zap XR	XL1-Blue MRF'	Stratagene	937208
37	human placenta #19	GT11	LE392	Clontech	HL1008
38	human liver 5'strech	GT11	LE392	Clontech	HL1115b
39	human uterus	Zap-CMV XR	XL1-Blue MRF'	Stratagene	980207
40	human kidney large-insert cDNA library	TriplEx2	XL1-Blue	Clontech	HL5507u

### Gene specific cloning primers for PCR

Pairs of PCR primers having a length of between 18 and 25 bases were designed for amplifying the full length sequence of the virtual cDNA using Primer Designer Software, as shown in Table 2 below (Scientific & Educational Software, PO Box 72045, Durham, NC 27722-2045, USA). PCR primers were optimized to have a  $T_m$  close to  $55 \pm 10^\circ\text{C}$  and a GC content of 40-60%. Primers were selected which had high selectivity for the target sequence IPAAA44548 (little or no none specific priming).

**Table II: INSP037 Cloning primers**

Primer	Name	Sequence (5'-3')	Position	$T_m^\circ\text{C}$	%GC
CP1	2C5 Forward primer	GCA TCA ACA ACA TCC AGT AA	28	58	40
CP2	2C6 Reverse Primer	CAT TCT AAA GTG TGC CAT CT	291C	57	40

### 10 PCR of virtual cDNAs from phage library DNA

Full-length virtual cDNA encoding IPAAA44548 (Figure 3) was obtained as a PCR amplification product of 264 bp (Figure 4) using gene specific cloning primers (CP1 and CP2, Figure 3 and Table 2). The PCR was performed in a final volume of 50 $\mu$ l containing 1X AmpliTaq<sup>TM</sup> buffer, 200  $\mu$ M dNTPs, 50 pmoles each of cloning primers primers, 2.5 units of AmpliTaq<sup>TM</sup> (Perkin Elmer) and 100 ng of each phage library DNA using an MJ Research DNA Engine, programmed as follows: 94  $^\circ\text{C}$ , 1 min; 40 cycles of 94  $^\circ\text{C}$ , 1 min,  $x^\circ\text{C}$ , and  $y$  min and 72  $^\circ\text{C}$ , (where  $x$  is the lowest  $T_m - 5^\circ\text{C}$  and  $y = 1$  min per kb of product); followed by 1 cycle at 72  $^\circ\text{C}$  for 7 min and a holding cycle at 4  $^\circ\text{C}$ .

20 The amplification products were visualized on 0.8 % agarose gels in 1 X TAE buffer (Life Technologies) and PCR products migrating at the predicted molecular mass were purified from the gel using the Wizard PCR Preps DNA Purification System (Promega). PCR products eluted in 50  $\mu$ l of sterile water were either sub-cloned directly or stored at  $-20^\circ\text{C}$ .

### Subcloning of PCR Products

PCR products were subcloned into the topoisomerase I modified cloning vector (pCR II TOPO) using the TOPO TA cloning kit purchased from the Invitrogen Corporation (cat. No. K4600-01 and K4575-01 respectively) using the conditions specified by the manufacturer. Briefly, 4 µl of gel purified PCR product from the human pituitary library (library number 3) amplification was incubated for 15 min at room temperature with 1 µl of TOPO vector and 1 µl salt solution. The reaction mixture was then transformed into *E. coli* strain TOP10 (Invitrogen) as follows: a 50 µl aliquot of One Shot TOP10 cells was thawed on ice and 2 µl of TOPO reaction was added. The mixture was incubated for 15 min on ice and then heat shocked by incubation at 42 °C for exactly 30 s. Samples were returned to ice and 250 µl of warm SOC media (room temperature) was added. Samples were incubated with shaking (220 rpm) for 1 h at 37 °C. The transformation mixture was then plated on L-broth (LB) plates containing ampicillin (100 µg/ml) and incubated overnight at 37 °C. Ampicillin resistant colonies containing cDNA inserts were identified by colony PCR.

### Colony PCR

Colonies were inoculated into 50 µl sterile water using a sterile toothpick. A 10 µl aliquot of the inoculum was then subjected to PCR in a total reaction volume of 20 µl as described above, except the primers pairs used were SP6 (5') and T7. The cycling conditions were as follows: 94 °C, 2 min; 30 cycles of 94 °C, 30 sec, 47 °C, 30 sec and 72 °C for 1 min; 1 cycle, 72 °C, 7 min. Samples were then maintained at 4 °C (holding cycle) before further analysis.

PCR reaction products were analyzed on 1 % agarose gels in 1 X TAE buffer. Colonies which gave the expected PCR product size (264 bp cDNA + 187 bp due to the multiple cloning site or MCS) were grown up overnight at 37 °C in 5 ml L-Broth (LB) containing ampicillin (50 µg /ml), with shaking at 220 rpm at 37 °C.

### Plasmid DNA preparation and Sequencing

Miniprep plasmid DNA was prepared from 5 ml cultures using a Qiaprep Turbo 9600 robotic system (Qiagen) or Wizard Plus SV Minipreps kit (Promega cat. no. 1460)



according to the manufacturer's instructions. Plasmid DNA was eluted in 100 µl of sterile water. The DNA concentration was measured using an Eppendorf BO photometer. Plasmid DNA (200-500 ng) was subjected to DNA sequencing with T7 primer and SP6 primer using the BigDyeTerminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer.

Example 3: Construction of plasmids for expression of INSP037 (IPAAA44548) in HEK293/EBNA cells

A pCRII-TOPO clone containing the full coding sequence (ORF) of IPAAA44548 identified by DNA sequencing (Figure 5) was then used to subclone the insert into the mammalian cell expression vector pEAK12d (Figure 6) using the Gateway™ cloning methodology (Invitrogen). The cloned sequence contains a single nucleotide substitution A134G (Figure 4).

Generation of Gateway compatible IPAAA44548 ORF fused to an in frame 6HIS tag sequence.

The first stage of the Gateway cloning process involves a two step PCR reaction which generates the ORF of IPAAA44548 flanked at the 5' end by an attB1 recombination site and Kozak sequence, and flanked at the 3' end by a sequence encoding an in frame 6 histidine (6HIS) tag, a stop codon and the attB2 recombination site (Gateway compatible cDNA). The first PCR reaction (in a final volume of 50 µl) contains: 25 ng of pCR II TOPO-IPAAA44548 (plasmid 13124 and Figure 5), 2 µl dNTPs (5mM), 5µl of 10X Pfx polymerase buffer, 0.5 µl each of gene specific primer (100 µM) (EX1 forward and EX1 reverse) and 0.5 µl Platinum Pfx DNA polymerase (Invitrogen). The PCR reaction was performed using an initial denaturing step of 95°C for 2 min, followed by 12 cycles of 94 °C, 15 sec and 68°C for 30 sec. PCR products were purified directly from the reaction mixture using the Wizard PCR prep DNA purification system (Promega) according to the manufacturer's instructions. The second PCR reaction (in a final volume of 50 µl) contained 10 µl purified PCR product, 2 µl dNTPs (5 mM), 5 µl of 10X Pfx

polymerase buffer, 0.5  $\mu$ l of each Gateway conversion primer (100  $\mu$ M) (GCP forward and GCP reverse) and 0.5  $\mu$ l of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: 95  $^{\circ}$ C for 1 min; 4 cycles of 94  $^{\circ}$ C, 15 sec; 45  $^{\circ}$ C, 30 sec and 68  $^{\circ}$ C for 3.5 min; 25 cycles of 94  $^{\circ}$ C, 15 sec; 55  $^{\circ}$ C, 30 sec and 68  $^{\circ}$ C, 3.5 min. PCR products were purified as described above.

Alternatively for expression of IPAAA44548 in *E.coli*, an ORF was generated which contained a Shine Dalgarno sequence upstream of the initiating methionine codon using gene specific primers (EX3 - forward and EX2 – reverse) in the first PCR, and primers GCPF and GCPR using the same conditions as described above. The resultant PCR product was called SD-IPAAA44548.

Subcloning of Gateway compatible IPAAA44548 ORF into Gateway entry vector pDONR201 and expression vector pEAK12d

The second stage of the Gateway cloning process involves subcloning of the Gateway modified PCR product into the Gateway entry vector pDONR201 (Invitrogen, Figure 7) as follows: 5  $\mu$ l of purified PCR product is incubated with 1.5  $\mu$ l pDONR201 vector (0.1  $\mu$ g/ $\mu$ l), 2  $\mu$ l BP buffer and 1.5  $\mu$ l of BP clonase enzyme mix (Invitrogen) at RT for 1 h. The reaction was stopped by addition of proteinase K (2  $\mu$ g) and incubated at 37 $^{\circ}$ C for a further 10 min. An aliquot of this reaction (2  $\mu$ l) was transformed into *E. coli* DH10B cells by electroporation using a Biorad Gene Pulser. Transformants were plated on LB-kanamycin plates. Plasmid mini-prep DNA was prepared from 1-4 of the resultant colonies using Wizard Plus SV Minipreps kit (Promega), and 1.5  $\mu$ l of the plasmid eluate was then used in a recombination reaction containing 1.5  $\mu$ l pEAK12d vector (Figure 6) (0.1  $\mu$ g /  $\mu$ l), 2  $\mu$ l LR buffer and 1.5  $\mu$ l of LR clonase (Invitrogen) in a final volume of 10  $\mu$ l. The mixture was incubated at RT for 1 h, stopped by addition of proteinase K (2  $\mu$ g) and incubated at 37 $^{\circ}$ C for a further 10 min. An aliquot of this reaction (1  $\mu$ l) was used to transform *E. coli* DH10B cells by electroporation.

Clones containing the correct insert were identified by performing colony PCR as described above except that pEAK12d primers (pEAK12d F and pEAK12d R) were used for the PCR. Plasmid mini prep DNA was isolated from clones containing the correct insert using a Qiaprep Turbo 9600 robotic system (Qiagen) or manually using

a Wizard Plus SV minipreps kit (Promega) and sequence verified using the pEAK12d F and pEAK12d R primers.

CsCl gradient purified maxi-prep DNA of plasmid pEAK12d-IPAAA44548-6HIS (plasmid ID number 11775, Figure 8) was prepared from a 500 ml culture of sequence  
5 verified clones (Sambrook J. et al., in Molecular Cloning, a Laboratory Manual, 2<sup>nd</sup> edition, 1989, Cold Spring Harbor Laboratory Press), resuspended at a concentration of 1 µg/µl in sterile water and stored at -20 C.

#### Construction of expression vector pEAK12d

The vector pEAK12d is a Gateway Cloning System compatible version of the  
10 mammalian cell expression vector pEAK12 (purchased from Edge Biosystems) in which the cDNA of interest is expressed under the control of the human EF1α promoter. pEAK12d was generated as described below:

pEAK12 was digested with restriction enzymes HindIII and NotI, made blunt ended with Klenow (New England Biolabs) and dephosphorylated using calf-intestinal  
15 alkaline phosphatase (Roche). After dephosphorylation, the vector was ligated to the blunt ended Gateway reading frame cassette C (Gateway vector conversion system, Invitrogen cat no. 11828-019) which contains AttR recombination sites flanking the ccdB gene and chloramphenicol resistance, and transformed into *E.coli* DB3.1 cells (which allow propagation of vectors containing the ccdB gene). Mini prep DNA was  
20 isolated from several of the resultant colonies using a Wizard Plus SV Minipreps kit (Promega) and digested with AseI / EcoRI to identify clones yielding a 670 bp fragment, indicating that the cassette had been inserted in the correct orientation. The resultant plasmid was called pEAK12d (Figure 6).

Subcloning of Gateway compatible SD - IPAAA44548 ORF into Gateway entry  
25 vector pDONR201 and *E.coli* expression vector pDEST14.

Gateway compatible SD-IPAAA44548 ORF containing an in frame 3' 6HIS tag coding sequence and a 5' upstream Shine Dalgarno sequence was subcloned into pDONR201 using BP clonase. The resultant plasmid was then used in a recombination reaction with the *E.coli* expression vector pDEST14 (purchased from  
30 Invitrogen, Figure 9) using LR clonase as described above. The resultant expression

plasmid (pDEST14-IPAAA44548-6HIS) (Figure 10, plasmid ID 12896) was sequence verified as described above. For expression in *E.coli*, CsCl purified maxi-prep DNA was re-transformed into *E.coli* host strain BL21. The expression of the inserted cDNA is under the control of a T7 promoter.

5 **Table 3: Primers for IPAAA44548 subcloning and sequencing**

Primer	Name	Sequence (5'-3')
GCP Forward	I-C1 attB1-K	G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC <u>GCC ACC</u>
GCP Reverse	22A3 attB2-stop-His6-R	GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA <i>ATG GTG ATG GTG ATG GTG</i>
GCP-SD Forward	III-A1 attB1-shineDalgarno-p	G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC <u>GAA GGA GA</u>
EX1 Forward	32A5 attB1p-IPAAA44548-1F	GCA GGC TTC <u>GCC ACC</u> ATG ACT TCA CCA AAC GAA CTA A
EX2 Reverse	32A8 IPAAA44548-H6p-234R	<i>GTG ATG GTG ATG GTG</i> AAG TGT GCC ATC TGC ATT TCT
EX3 forward	II-I8 44548ShineDalgarno-1F	AAA GCA GGC TTC <u>GAA GGA</u> GAT ATA CAT ATG ACT TCA CCA AAC GAA CT
pEAK12-F	32D1	GCC AGC TTG GCA CTT GAT GT
pEAK12-R	32D2	GAT GGA GGT GGA CGT GTC AG
SP6		ATT TAG GTG ACA CTA TAG
T7		TAA TAC GAC TCA CTA TAG GG
pDEST14-R		TGG CAG CAG CCA ACT CAG CTT

Underlined sequence = Kozak sequence

**Bold** = Stop codon

*Italic* sequence = His tag

Shaded sequence = Shine Dalgarno sequence (Ribosome binding site)

Example 4: Identification of cDNA libraries containing IPAAA44548

PCR products obtained with CP1 and CP2 and migrating at the correct size (264 bp) were identified in libraries 3, 8 and 12 (pituitary, brain cortex and fetal kidney respectively).

5    Example 5: Expression in mammalian cells of the cloned, IPAAA44548-S-6HIS (plasmid number 12118)

Cell culture

Human Embryonic Kidney 293 cells expressing the Epstein-Barr virus Nuclear Antigen (HEK293-EBNA, Invitrogen) were maintained in suspension in Ex-cell  
10    VPRO serum-free medium (seed stock, maintenance medium, JRH). Sixteen to 20 hours prior to transfection (Day-1), cells were seeded in 2x T225 flasks (50 ml per flask in DMEM / F12 (1:1) containing 2% FBS seeding medium (JRH) at a density of  $2 \times 10^5$  cells/ ml). The next day (transfection day0) the transfection took place by using the JetPEI<sup>TM</sup> reagent (2  $\mu$ l/ $\mu$ g of plasmid DNA, PolyPlus-transfection). For each flask,  
15    113  $\mu$ g of plasmid (No. 12118) was co-transfected with 2.3  $\mu$ g of GFP (fluorescent reporter gene). The transfection mix was then added to the 2xT225 flasks and incubated at 37°C (5%CO<sub>2</sub>) for 6 days.

Confirmation of positive transfection was done by qualitative fluorescence examination at day 1 and day 6 (Axiovert 10 Zeiss).

20    On day 6 (harvest day), supernatants (100ml) from the two flasks were pooled and centrifuged (4°C, 400g) and placed into a pot bearing a unique identifier.

One aliquot (500ul) was kept for QC of the 6His-tagged protein (internal bioprocessing QC).

Scale-up batches were produced following the protocol called "PEI transfection of  
25    suspension cells" referenced BP / PEI/ HH/02/04 with PolyEthyleneImine from Polysciences as transfection agent.

This protocol was based on the following proportions:

For 400 ml spinner: 1E6 hek293EBNA cells / ml in 200ml FEME 1% FBS

400 µg (plasmid No. 12118) diluted into 10ml FEME 1% and 800ug PEI added

90 minutes post-transfection, FEME 1% medium added to reach 400-ml total volume.

Spinner left in culture for 6 days until harvest.

## 5 Purification process

The culture medium sample (100 or 400 ml) containing the recombinant protein with a C-terminal 6His tag was diluted with one volume cold buffer A (50 mM NaH<sub>2</sub>PO<sub>4</sub>; 600 mM NaCl; 8.7 % (w/v) glycerol, pH 7.5) to a final volume of 200 and 800 ml, respectively. The sample was filtered through a 0.22 µm sterile filter (Millipore, 500 ml filter unit) and kept at 4°C in a sterile square media bottle (Nalgene).

The purification was performed at 4°C on the VISION workstation (Applied Biosystems) connected to an automatic sample loader (Labomatic). The purification procedure was composed of two sequential steps, metal affinity chromatography on a Poros 20 MC (Applied Biosystems) column charged with Ni ions (4.6 x 50 mm, 0.83 ml), followed by gel filtration on a Sephadex G-25 medium (Amersham Pharmacia) column (1,0 x 10 cm).

For the first chromatography step the metal affinity column was regenerated with 30 column volumes of EDTA solution (100 mM EDTA; 1 M NaCl; pH 8.0), recharged with Ni ions through washing with 15 column volumes of a 100 mM NiSO<sub>4</sub> solution, washed with 10 column volumes of buffer A, followed by 7 column volumes of buffer B (50 mM NaH<sub>2</sub>PO<sub>4</sub>; 600 mM NaCl; 8.7 % (w/v) glycerol, 400 mM; imidazole, pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15 mM imidazole. The sample was transferred, by the Labomatic sample loader, into a 200 ml sample loop and subsequently charged onto the Ni metal affinity column at a flow rate of 10 ml/min. In case of the 400 ml scale up samples the transfer and charging procedure was repeated 4 times. The column was subsequently washed with 12 column volumes of buffer A, followed by 28 column volumes of buffer A containing 20 mM imidazole. During the 20 mM imidazole wash loosely attached contaminating proteins were elution of the column. The recombinant His-

tagged protein was finally eluted with 10 column volumes of buffer B at a flow rate of 2 ml/min, and the eluted protein was collected in a 1.6 ml fraction.

For the second chromatography step, the Sephadex G-25 gel-filtration column was regenerated with 2 ml of buffer D (1.137 M NaCl; 2.7 mM KCl; 1.5 mM  $\text{KH}_2\text{PO}_4$ ; 8 mM  $\text{Na}_2\text{HPO}_4$ ; pH 7.2), and subsequently equilibrated with 4 column volumes of buffer C (137 mM NaCl; 2.7 mM KCl; 1.5 mM  $\text{KH}_2\text{PO}_4$ ; 8 mM  $\text{Na}_2\text{HPO}_4$ ; 20 % (w/v) glycerol; pH 7.4). The peak fraction eluted from the Ni-column was automatically through the integrated sample loader on the VISION loaded onto the Sephadex G-25 column and the protein was eluted with buffer C at a flow rate of 2 ml/min. The desalted sample was recovered in a 2.2 ml fraction. The fraction was filtered through a 0.22  $\mu\text{m}$  sterile centrifugation filter (Millipore), frozen and stored at  $-80^\circ\text{C}$ . An aliquot of the sample was analyzed on SDS-PAGE (4-12 % NuPAGE gel; Novex) by coomassie staining and Western blot with anti-His antibodies.

Coomassie staining. The NuPAGE gel was stained in a 0.1 % coomassie blue R250 staining solution (30 % methanol, 10 % acetic acid) at room temperature for 1 h and subsequently destained in 20 % methanol, 7.5 % acetic acid until the background was clear and the protein bands clearly visible.

Western blot. Following the electrophoresis the proteins were electrotransferred from the gel to a nitrocellulose membrane at 290 mA for 1 hour at  $4^\circ\text{C}$ . The membrane was blocked with 5 % milk powder in buffer E (137 mM NaCl; 2.7 mM KCl; 1.5 mM  $\text{KH}_2\text{PO}_4$ ; 8 mM  $\text{Na}_2\text{HPO}_4$ ; 0.1 % Tween 20, pH 7.4) for 1 h at room temperature, and subsequently incubated with a mixture of 2 rabbit polyclonal anti-His antibodies (G-18 and H-15, 0.2  $\mu\text{g}/\text{ml}$  each; Santa Cruz) in 2.5 % milk powder in buffer E overnight at  $4^\circ\text{C}$ . After further 1 hour incubation at room temperature, the membrane was washed with buffer E (3 x 10 min), and then incubated with a secondary HRP-conjugated anti-rabbit antibody (DAKO, HRP 0399) diluted 1/3000 in buffer E containing 2.5 % milk powder for 2 hours at room temperature. After washing with buffer E (3 x 10 minutes), the membrane was developed with the ECL kit (Amersham Pharmacia) for 1 min. The membrane was subsequently exposed to a Hyperfilm (Amersham Pharmacia), the film developed and the western blot image visually analysed.

Protein assay. The protein concentration was determined using the BCA protein assay kit (Pierce) with bovine serum albumin as standard in samples that showed detectable protein bands by coomassie staining.

Expression of IPAAA44548-SEC- 6HIS in bacterial cells (plasmid No. 12896)

- 5 The method below describes the use of *E. Coli* BL-21 DE3 bacterial strain for producing the protein. "BL21 DE3" are part of T7 RNA polymerase-based expression systems widely used for over-expressing recombinant proteins.

Transformation of bacterial strain BL21 (DE3):

- We used the procedure of TSS method, the protocol has been taken from: Chung, C.T  
10 et al., Proc. Natl. Acad. Sci. USA (1989) 86:2172-2175.

- 10-100 ng DNA (2 µl) of the recombinant plasmid No. 12896 were added to competent BL21 for TSS method and placed 20 minutes on ice. SOC medium (0.8 ml) were added and the tube was incubated at 37°C, 200 rpm for 1 hour. From this culture 20 µl and 200 µl were sampled and plated on LB plates containing Ampicillin  
15 (40 µg/ml final concentration) and left overnight at 37°C.

The next day, 3 colonies were isolated and used for preparation of the glycerol stocks, tested for expression in shake flasks experiments before transferring production into a fermenter (one out of the three was chosen for large scale, as they were all performing the same in shake flasks).

- 20 Preparation of a seed stock for long term storage of the recombinant *E. Coli* strain:

- A 5 ml tube containing LB medium with Ampicillin 40 µg/ml (final concentration) was inoculated with a single colony from a fresh agar plate. Bacteria were grown overnight at 37 C, 200 rpm. The next morning, 50 µl of the overnight culture was sampled in order to inoculate a fresh 5 ml LB tube (+ antibiotics) and incubated 2-3  
25 hours at 37°C, 200 rpm in order to bring bacteria to the exponential growth phase.

5 ml glycerol at 20 % was then added to the culture and mixed. 1.5 ml were dispensed in each of 5 cryogenic vials which constitute a seed stock stored at -80°C (internal Glycerol stock).



Expression at the 5-litre scale:

The recombinant strain was propagated in a 5-litres Biolafitte stirred tank reactor (working containing 5-litres of ECPM 1 medium (having a composition as reported in Table 4) with appropriate antibiotic (40 µg/ml final concentration) and 0.5 % Glucose in order to avoid pre-induction of the T7 promoter. Only The research-grade run 2464 was prepared and sent to purification.

The inoculum was prepared in a 500-ml LB (+ antibiotics, 0.5 % Glucose) shake flask starting from one loop of frozen bacteria (scraped from one of the glycerol seed stock vial) and grown for 9 hours before automatic inoculation. When cells reached OD 10, (usually after 7 to 9 hours growth), the protein production was induced with IPTG: 1 mM final concentration. Induction lasted 3 hours.

Fermenter setting conditions throughout growth and induction were set at: 50 % dissolved oxygen concentration, 300 to 700 rpm depending on pO<sub>2</sub>, pH7.0. The PO<sub>2</sub> was maintained by air sparging +/- O<sub>2</sub> at 25 ml/min. A 5-ml sample was taken every hour and optical density was measured at 600 nm.

The cells were harvested and centrifuged at 4 000 rpm (in Sorvall RC 3B). The pellet was kept frozen at -20 °C until further processing.

Presence of the protein in the cells extract was assessed by Coomassie staining of a SDS-PAGE.

**Table 4 : ECPM1 composition**

Component	Source	Comment	Conc.	Unit	Steril.	Type
CaCl <sub>2</sub> .2H <sub>2</sub> O	STOCK SOL.	stock sol.=1.32 g/l	10	ml/l	HT	MAIN
CAS.AA	Sigma	Enzymatic Hydrolysate	20	g/l	HT	MAIN
GLYCEROL	0.87	or anhydrous glycerol	46	g/l	HT	MAIN
K <sub>2</sub> HPO <sub>4</sub>	STOCK-SOL.	stock sol. = 400 g/l	10	ml/l	HT	MAIN
K <sub>2</sub> SO <sub>4</sub>	STOCK SOL	Stock Sol=104 g/l	22.7	ml/l	HT	MAIN
KH <sub>2</sub> PO <sub>4</sub>	STOCK SOL.	stock sol.= 100 g/l	10	ml/l	HT	MAIN
MgCl <sub>2</sub> .6H <sub>2</sub> O	stock sol	Stock Sol= 1M	2	ml/l	FI	ADD
NH <sub>4</sub> Cl	STOCK SOL.	stock sol.= 100 g/l	10	ml/l	HT	MAIN

TRACE Elements (see Y.E	STOCK SOL.  Difco	stock sol composition in TRACE 1	10  3	ml/l  g/l	HT  HT	MAIN  MAIN
-------------------------------	-------------------------	-------------------------------------	-------------	-----------------	--------------	------------------

A few drops of Antifoam PPG P2000 are added.

**Table 5 : Trace Elements**

Component	Comment	Conc	Unit	Steril.	Type
Amonium molb	adjust pH 7-8 as necessary	0.01	g/l	HT	MAIN
Co(NO <sub>3</sub> ) <sub>2</sub> 6H <sub>2</sub> O		0.01	g/l	HT	MAIN
CuCl <sub>2</sub> 2H <sub>2</sub> O		0.01	g/l	HT	MAIN
EDTA	dissolved in approx.800ml	5	g/l	HT	MAIN
FeCl <sub>3</sub> 6H <sub>2</sub> O		0.5	g/l	FI	MAIN
ZnO		0.05	g/l	HT	MAIN

Each element was separately dissolved in HCl.

#### Purification process

- 5 67 g of the frozen bacteria paste was suspended in 270 ml of buffer A (50 mM NaH<sub>2</sub>PO<sub>4</sub>; 600 mM NaCl; 1 mM PMSF; 1 mM benzamidine; 8.7 % (w/v) glycerol, pH 7.5) supplemented with 1 tablet of complete EDTA-free protease inhibitors (Roche) /50 ml. The bacteria were disrupted by two passages through the Z-plus cell disrupter (Constant Cell Disruption Systems) at 1300 bar.
- 10 The sample was subsequently centrifuged at 36,000 x g for 30 min. The supernatant (300 ml) was loaded, at a flow rate of 4 ml/min, onto a Ni-NTA-Agarose column (2.5 x 3.0 cm) equilibrated in buffer A.

- 15 The column was washed with 100 ml buffer A followed by 85 ml 20 mM imidazole in buffer A. Proteins were eluted at a flow rate of 3 ml/min by a 300 ml linear gradient of 20 to 250 mM imidazole in buffer A and fractions of 7.5 ml were collected. A sample of every second fraction was diluted 1/6 in reducing SDS-sample buffer, 15 ul loaded /well on a 4-12 % NuPage gel (Novex) and after electrophoresis the gel was stained with coomassie blue.

- 20 Fractions with the highest IPAAA44548 concentration (fractions 36-42) were pooled, total volume was 53 ml (Pool N1). Fractions on both sides of pool N1 with a lower

purity and concentration (fractions 32-35 + 43-44) were pooled into pool N2 with a volume of 44 ml.

The pools from the Ni-column were further purified on a Q-Sepharose Fast flow column (1.5 x 12 cm) equilibrated in buffer B (50 mM Tris-HCl, 1 mM benzamidine, pH 7.5). 52 ml of pool N1 was diluted with 300 ml buffer B and 648 ml H<sub>2</sub>O to a final volume of 1000 ml. The sample was loaded onto the column at a flow rate of 5 ml/min, the column washed with 150 ml buffer B and proteins were eluted with a 160 ml linear gradient of 0 to 400 mM NaCl in buffer B. Fractions of 2 ml were collected and analyzed by coomassie stained SDS-PAGE as described above. Fractions 28-30 (Pool Q1) contained one protein band at the expected molecular weight of 9.6 kDa. Fractions 31-33 (Pool Q2) in addition contained a protein band at approximately 20 kDa, indicating dimer formation.

43 ml of pool N2 from the Ni-column was diluted with 300 ml buffer B and 657 ml H<sub>2</sub>O to 1000 ml. The sample was loaded onto the Q-Sepharose column, the protein was eluted and fractions analyzed as described for pool N1. Fractions 28-30 (Pool Q3) contained one protein band at the expected molecular weight of 9.6 kDa. Each Q-pool had a volume of 5.5 ml.

The pools from the Q-Sepharose column were passed over a Superdex G75 gel filtration column (HiLoad 16/60, Pharmacia). The column was washed with 0.5 M NaOH and equilibrated in PBS. The column was run at a flow rate of 1 ml/min and 5 ml of the pools was loaded onto the column. Fractions of 2 ml were collected and analyzed by coomassie stained SDS-PAGE as described above.

IPAAA44548 from pool Q1 eluted in fractions 31-35 (9.5 ml) (S1), from pool Q2 the protein eluted in two peaks, in fraction 31-34 (7.5 ml) (S2) and in fractions 26-28 (5.8 ml) (S3), and the protein in pool Q3 eluted in fractions 32-35 (7.5 ml) (S4). When analyzed on non-reducing SDS-PAGE pool S3 showed to contain over 80 % of the protein as dimers, whereas the other pools contained only traces of dimers. The pools S1 and S2 had comparable purity and concentration and were pooled into one pool S1b (9.5+7.5=17 ml).

Protein concentrations were determined by measuring absorption at 280 nm, using the calculated molar extinction coefficient of 7,090 and molecular weight of 9,625. The

molecular mass of the protein, determined by mass spectrometry, was found to be 9,624.6 in pools S1b and S4. The molecular mass in pool S3 was determined to be 19,252.2, confirming disulphide bridged dimers in this pool. The pools were assayed for LPS and contained between 1.1 and 3.4 U/mg.

## 5 Summary of the purified pools:

Pool	Concentration	Total amount	Lot number
Pool S1b	2.1 mg/ml	35.7 mg	2
Pool S3	1.7 mg/ml	9.8 mg	3
Pool S4	0.95 mg/ml	7.1 mg	6

- 10 A total of 52 mg pure protein was recovered, or 0.77 mg/g bacteria paste. All three pools were over 97 % pure on RP-HPLC.

### Example 6: *In vivo* characterisation of IPAA44548 (INSP037)

- The IPAA44548 (INSP037) protein (IPAAA44548-6-HIS and IPAAA44548-ATT-6HIS) was shown *in vitro* to induce IFN $\gamma$  secretion by Concanavalin A (ConA) and
- 15 Phytohemagglutinin (PHA)-stimulated human peripheral blood mononuclear cells (hPBMC) (preliminary data, not shown). On the basis of those data, it was decided to test the activity of IPAAA44548 (INSP037) in an *in vivo* ConA model by electrotransfer, as described below.

### Concanavalin A (ConA)-induced liver hepatitis

- 20 Toxic liver disease represents a worldwide health problem in humans for which pharmacological treatments have yet to be discovered. For example, active chronic hepatitis leading to liver cirrhosis is a disease state, in which liver parenchymal cells are progressively destroyed by activated T cells. ConA-induced liver toxicity is one of three experimental models of T-cell dependent apoptotic and necrotic liver injury
- 25 described in mice. Gal N ( D-Galactosamine) sensitized mice challenged with either activating anti-CD3 monoclonal AB or with superantigen SEB develop severe apoptotic and secondary necrotic liver injury (Kusters S, Gastroenterology. 1996 Aug;111(2):462-71). Injection of the T-cell mitogenic plant lectin ConA to non-

sensitized mice results also in hepatic apoptosis that preceeds necrosis. ConA induces the release of systemic TNF $\alpha$  and IFN $\gamma$  and various other cytokines. Both TNF $\alpha$  and IFN $\gamma$  are critical mediators of liver injury. Transaminase release 8 hours after the insult indicates severe liver destruction.

- 5 Several cell types have been shown to be involved in liver damage, including CD4 T cells, macrophages and natural killer cells (Kaneko J Exp Med 2000, 191, 105-114). Anti-CD4 antibodies block activation of T cells and consequently liver damage (Tiegs et al. 1992, J Clin Invest 90, 196-203). Pre-treatment of mice with monoclonal antibodies against CD8 failed to protect, whereas deletion of macrophages prevented  
10 the induction of hepatitis.

- A study was undertaken to investigate the role of IPAA44548, a IFN $\gamma$  like protein, in ConA-induced liver hepatitis. Several cytokines have been shown either to be critical in inducing or in conferring protection from ConA-induced liver damage. TNF $\alpha$  for example is one of the first cytokines produced after ConA injection and anti-TNF $\alpha$   
15 antibodies confer protection against disease (Seino et al. 2001, Annals of surgery 234, 681). IFN $\gamma$  appears also to be a critical mediator of liver injury, since anti-IFN $\gamma$  antiserum significantly protect mice, as measured by decreased levels of transaminases in the blood of ConA-treated animals (see Kusters et al., above). In liver injury, increased production of IFN $\gamma$  was observed in patients with autoimmune  
20 or viral hepatitis. In addition transgenic mice expressing IFN $\gamma$  in the liver develop liver injury resembling chronic active hepatitis (Toyonaga et al. 1994, PNAS 91, 614-618). IFN $\gamma$  may also be cytotoxic to hepatocytes, since *in vitro* IFN $\gamma$  induces cell death in mouse hepatocytes that was accelerated by TNF (Morita et al. 1995, Hepatology 21, 1585-1593).

- 25 Other molecules have been described to be protective in the ConA model. A single administration of rhIL-6 completely inhibited the release of transaminases (Mizuhara et al. 1994, J. Exp. Med. 179, 1529-1537).

cDNA electrotransfer into muscle fibers in order to achieve systemic expression of a protein of interest

- 30 Among the non-viral techniques for gene transfer *in vivo*, the direct injection of

plasmid DNA into the muscle and subsequent electroporation is simple, inexpensive and safe. The post-mitotic nature and longevity of myofibers permits stable expression of transfected genes, although the transfected DNA does not usually undergo chromosomal integration (Somieri et al. 2000, Molecular Therapy 2,178).

5 Several reports have demonstrated that secretion of muscle-produced proteins into the blood stream can be achieved after electroporation of corresponding cDNAs (Rizzuto et al. PNAS, 1996, 6417; Aihara H et al., 1998, Nature Biotech 16, 867). In addition, *in vivo* efficacy of muscle expressed Epo and IL-18BP in disease models has been shown (Rizzuto, 2000, Human Gene Therapy 41, 1891; Mallat, 2001, Circulation

10 research 89, 41).

The following material and methods were employed in this Example:

#### Animals

In all the studies male C57/BL6 male (8 weeks old) were used. In general, 7 animals per experimental group are used. Mice were maintained in standard conditions under

15 a 12-hour light-dark cycle, provided irradiated food and water *ad libitum*.

#### Muscle Electrotransfer

##### *Choice of vector*

His or StrepII tagged hIL-6 or IPAAA44548 genes were cloned in the Gateway compatible pDEST12.2 containing the CMV promoter.

##### 20 *Electroporation Protocol*

Mice were anaesthetised with gas (isofluran, Baxter, Ref: ZDG9623). Hindlimbs were shaved and an echo graphic gel was applied. Hyaluronidase was injected in the posterior tibialis muscle with (20U in 50 µl sterile NaCl 0.9%, Sigma, Ref. H3631). After 10 min, 100 µg of plasmid (50 µg per leg in 25 µl of sterile NaCl 0.9%) was

25 injected in the same muscle. The DNA was prepared in the Buffer PBS-L-Glutamate (6 mg/ml; L-Glutamate, Sigma, P4761) before intra-muscular injection. For electrotransfer, the electric field was applied for each leg with the ElectroSquarePorator (BTX, ref ECM830) at 75 Volts during 20 ms for each pulse, 10 pulses with an interval of 1 second in a unipolar way with 2 round electrodes (size 0.5

mm diameter) (Mir LM et al, Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4262-7 and Haas K et al., Neuron. 2001 Mar;29(3):583-91.).

### Readouts

#### *Blood Sampling*

- 5 100 µl of blood was sampled from the eye at various 1.30h, 6h and 8h time-points. At the time of sacrifice, blood was taken from the heart.

#### *Detection of cytokines and transaminases in blood samples*

- IL-2, IL-5, IL-4, TNF $\alpha$  and IFN $\gamma$  cytokine levels were measured using the TH1/TH2 CBA assay (BD 551287). ASpartate AminoTransferase (ASAT), ALanine Amino  
10 Transferase ALAT and urea blood parameters were determined using the COBAS instrument (Hitachi).

### ConA induction

- Mice female C57/B16 (from IFFA CREDO), 8 weeks old animals; ConA (purchased from Sigma, ref.C7275). ConA was injected at different doses at time 0 i.v and blood  
15 samples were taken at 1.30, 6 or 8 hours post-injection. Cytokine and ASAT ALAT measurements were performed like described above.

#### *IL-6 pretreatment in the ConA model*

CHO cell produced hIL-6 was injected 1 hour before ConA injection.

#### *IPAAA44548 and IL-6 electrotransfer*

- 20 At day 0 electrotransfer of IPAAA44548 or hIL-6 vectors as well as the empty vector (negative control) was performed (according to the above protocol). At day 5 after electrotransfer, ConA (20mg/kg) was injected iv and blood sampled at 3 time-points (1.30, 6, 24 hours). Cytokines, ASAT and ALAT measurements were performed like described above.

### 25 Results

*In vivo*, in this murine model of ConA-induced fulminant hepatitis, treatment using

cDNA electrotransfer with IPAAA44548 showed an increase in circulating levels of TNF- $\alpha$ , IL-2, and IFN- $\gamma$  (see Figure 17 A-C). In addition ASAT and ALAT levels were increased with respect to the control (Figure 17, D and E).

5 Results in Figure 18 A-F represent the positive control of the experiment (rhIL-6 known to block pro-inflammatory response induced by ConA). We used either the pDEST12.2hIL-6-STREPII or the pDEST12.2 STREPII electrotransfer vectors in order to express hIL-6 in the blood and thus show subsequent protection from ConA induced liver toxicity.

10 Our experiments show that expression of IPAAA44548 protein in serum using electrotransfer increases the level of pro-inflammatory cytokines at a systemic level after ConA challenge and exacerbates liver disease as measured by increased transaminase levels.

15 These results confirm the predicted IFN $\gamma$ -like activity of IPAAA44548 and open a series of interesting therapeutic applications for the protein *per se*. For example, known applications of IFN $\gamma$  may now be investigated for suitability to IPAAA44548 (e.g. anti-cancer activity). It will also now be possible to identify inhibitors or antagonists of IPAAA44548, such as for example monoclonal antibodies, which may be of use in further studies of IPAAA44548 activity *in vivo* or in clinical applications.



**INSP037 Sequence Information:****SEQ ID NO: 1 (Nucleotide sequence of INSP037)**

1 ATGACTTCAC CAAACGAACT AAATAAGCTG CCATGGACCA ATCCTGGAGA  
5 51 AACAGAGATA TGTGACCTTT CAGACACAGA ATTCAAAATA TCTGTGTTGA  
101 AGAACCTCAA AGAAATTCAA GATAACACAG AGAAGGAATC CAGAATTCTA  
151 TCAGACAAAT ATAAGAAACA GATTGAAATA ATTAAAGGGA ATCAAGCAGA  
201 AATTCTGGAG TTGAGAAATG CAGATGGCAC ACTTTAG

**10 SEQ ID NO: 2 (Protein sequence of INSP037)**

1 MTSPNELNKL PWTNPGETEI CDLSDETFKI SVLKNLKEIQ DNTEKESRIL  
51 SDKYKKQIEI IKGNQAEILE LRNADGTL

**CLAIMS**

1. A polypeptide, which polypeptide:
  - (i) comprises or consists of the amino acid sequence as recited in SEQ ID NO:2;
  - (ii) is a fragment thereof that is an interferon gamma-like secreted protein of the  
5 four helical bundle cytokine fold, or having an antigenic determinant in  
common with the polypeptides of (i); or
  - (iii) is a functional equivalent of (i) or (ii).
2. A polypeptide according to claim 1 which functions as an interferon gamma-like secreted protein of the four helical bundle cytokine fold.
- 10 3. A polypeptide which is a functional equivalent according to part (iii) of claim 1, is homologous to the amino acid sequence as recited in SEQ ID NO:2 and is an interferon gamma-like secreted protein of the four helical bundle cytokine fold.
4. A fragment or functional equivalent according to any one of the preceding claims, which has greater than 80% sequence identity with the amino acid sequence  
15 recited in SEQ ID NO:2 or with active fragments thereof, preferably greater than 90%, 95%, 98% or 99% sequence identity.
5. A functional equivalent according to any one of the preceding claims, which exhibits significant structural homology with a polypeptide having the amino acid sequence given in SEQ ID NO:2.
- 20 6. A fragment as recited in any one of claims 1, 2 or 4 having an antigenic determinant in common with a polypeptide of part (i) of claim 1 which consists of 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more) amino acid residues from the sequence of SEQ ID NO:2.
7. A purified nucleic acid molecule which encodes a polypeptide according to any  
25 one of the preceding claims.
8. A purified nucleic acid molecule according to claim 7, which has the nucleic acid sequence as recited in SEQ ID NO:1 or is a redundant equivalent or fragment thereof.
9. A purified nucleic acid molecule which hybridizes under high stringency  
30 conditions with a nucleic acid molecule according to claim 7 or claim 8.

10. A vector comprising a nucleic acid molecule as recited in any one of claims 7-9.
11. A host cell transformed with a vector according to claim 10, a host cell according to claim 11.
12. A ligand which binds specifically to, and which preferably inhibits the interferon gamma-like activity of, a polypeptide according to any one of claims 1-6.
13. A ligand according to claim 12, which is an antibody.
14. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1-6.
15. A compound according to claim 14 that binds to a polypeptide according to any one of claims 1-6 without inducing any of the biological effects of the polypeptide.
16. A compound according to claim 14 or claim 15, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
17. A polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 12 or claim 13, or a compound according to any one of claims 14-16, for use in therapy or diagnosis of disease.
18. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of claims 1-6, or assessing the activity of a polypeptide according to any one of claims 1-6, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.
19. A method according to claim 18 that is carried out *in vitro*.
20. A method according to claim 18 or claim 19, which comprises the steps of: (a) contacting a ligand according to claim 12 or claim 13 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.
21. A method according to claim 18 or claim 19, comprising the steps of:
  - a) contacting a sample of tissue from the patient with a nucleic acid probe under

stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 7-9 and the probe;

- b) contacting a control sample with said probe under the same conditions used in step a); and
- 5 c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

22. A method according to claim 18 or claim 19, comprising:

- 10 a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 7-9 and the primer;
- b) contacting a control sample with said primer under the same conditions used in step a); and
- 15 c) amplifying the sampled nucleic acid; and
- d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

20 23. A method according to claim 18 or claim 19 comprising:

- a) obtaining a tissue sample from a patient being tested for disease;
- b) isolating a nucleic acid molecule according to any one of claims 7-9 from said tissue sample; and
- 25 c) diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.

24. The method of claim 23, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.

30 25. The method of either claim 23 or 24, wherein the presence or absence of the

mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any  
5 portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.

26. A method according to any one of claims 18-25, wherein said disease is selected from immune disorders, such as autoimmune disease, rheumatoid arthritis,  
10 osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myasthenia gravis, Guillain-Barré syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis and graft-versus-host disease, monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy,  
15 rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-  
20 obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease, aggressive and chronic periodontitis, cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas,  
25 mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis, AIDS, AIDS related  
30 complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidomycosis, paracoccidiomycosis and candidiasis,

diseases associated with antimicrobial immunity, Peyronie's disease, tuberculosis, and viral infection.

27. Use of a polypeptide according to any one of claims 1-6 as an interferon gamma-like secreted protein of the four helical bundle cytokine fold.
- 5 28. A pharmaceutical composition comprising a polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 11 or 12, or a compound according to any one of claims 14-16.
29. A vaccine composition comprising a polypeptide according to any one of claims 10 1-6 or a nucleic acid molecule according to any one of claims 7-9.
30. A polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 11 or 12, a compound according to any one of claims 14-16, or a pharmaceutical composition according to claim 28, for use in the manufacture of a medicament for the treatment of a 15 disease selected from immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myasthenia gravis, Guillain-Barré syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis and graft-versus-host disease, monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory 20 disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, 25 post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease, aggressive and chronic periodontitis, cancers including carcinomas, sarcomas, lymphomas, 30 renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas, mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological

- disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis, AIDS, AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity, Peyronie's disease, tuberculosis, and viral infection.
31. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 11 or 12, or a compound according to any one of claims 14-16, or a pharmaceutical composition according to claim 28.
32. A method according to claim 31, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.
33. A method according to claim 31, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.
34. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of claims 1-6, or the level of expression of a nucleic acid molecule according to any one of claims 7-9 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.

35. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1-6, or a nucleic acid molecule according to any one of claims 7-9 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.
36. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 7-9; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
37. The kit of claim 36, further comprising a third container holding an agent for digesting unhybridised RNA.
38. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 7-9.
39. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of claims 1-6; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.
40. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1-6.
41. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 40 with a candidate compound and determining the effect of the compound on the disease of the animal.
42. A method according to claims 31-37 or claim 41, wherein said disease is one of the diseases set forth in claim 30.



1/24

Figure 1

Num	PDB Code	Norm Align Score	Raw Align Score	%ID	%Struc Aligned	%Query Seq Aligned	Pairwise Energy	Solvation Energy	Neutral Net Score	% Confidence	From Pos for Query	To Pos for Query	From Pos for Target	To Pos for Target	Alignment Length	Local=0 Global=1
1	1d3paa0 biopendium (align)	38.21	60	37.8	31.5	46.2	-17.99	-0.17	0.957	84	30	66	20	55	37	0
2	1d3paa0 biopendium (align)	36.91	59	37.8	29.4	46.2	-18.54	0.08	0.953	83	30	66	28	63	37	0
3	1d3paa0 biopendium (align)	36.84	59	37.8	28.9	46.2	-17.34	1.14	0.951	82	30	66	30	65	37	0
4	1d3paa0 biopendium (align)	33.91	56	37.8	29.4	46.2	-8.35	0.60	0.940	78	30	66	30	65	37	0
5	1d3paa0 biopendium (align)	30.16	56	31.9	15.5	59.0	-15.63	-0.64	0.922	72	21	67	190	234	47	0

&lt;&lt;Previous 1 Next&gt;&gt;

2/24

Figure 2

## Alignment

```

Alignment Type: Local
Sequence A Range: 1 -> 111
Sequence B Range: 1 -> 78
Gap Open Penalty: -11
Gap Extend Penalty: -1
Scoring Matrix: /usr/local/BLOSUM62
Profile A: ../gtws_files/profiles/ld9gBB00.pro
Sequence B: /tmp/gtw_6314.fa
DB Alignment: -
GT Alignment: -
View Alignment: Yes
Reverse GT Alignment: No
Score Length Num_ID No.+ve Ovr1p %ID %+ve From To From To
SCORES: 60 37 14 19 68 37.8 51.4 20 55 30 66
Length1 Length2 Normalised-Score
SCORE2: 111 78 38.210598

10| 20| 30| 40| 50| 60
ld9gBB00 -----qffreienlkeyfnggplfSEILKNWKDESDKKIIQSQIVS-FYFKLFENLKDQViqra
. . . . .
IPAAA445 mtspnlnklpwtnpgetaieclsdtefkISVLKNLKEIQDNTEKESBRILSDKYKKQIEIIKGNQAeile
10| 20| 30| 40| 50| 60| 70|

70| 80| 90| 100| 110|
ld9gBB00 mdiikqdmfQkFlngssekledfkkliqipvddlqiqrkainelikvndls
IPAAA445 lrnadgtl-----

```

3/24

Figure 3

INSP037 (IPAAA44548) Predicted sequence with translation product:

```
1  TGCCTAGACA CCAAAGAACA ACTATTAGCA TCAACAACAT CCAGTAAAAC ATGACTTCAC CAAACGAACT
                                     m t s p n e

71  AAATAAGCTG CCATGGACCA ATCCTGGAGA AACAGAGATA TGTGACCTTT CAGACACAGA ATTCAAATA
    l n k l p w t n p g e t e i c d l s d t e f k i

141 TCTGTGTTGA AGAACCTCAA AGAAATTCAA GATAACACAG AGAAGGAATC CAGAATTCTA TCAGACAAAT
    s v l k n l k e i q d n t e k e s r i l s d k

211 ATAAGAAACA GATTGAAATA ATTAAAGGGA ATCAAGCAGA AATTCTGGAG TTGAGAAATG CAGATGGCAC
    y k k q i e i i k g n q a e i l e l r n a d g

281 ACTTTAGAAT GCATAAGAGT CTTTTTATAG CAGAATTCAT CAAGCAGAAG AAAGAAT
    t l
```

The position of primers is denoted by the shaded boxes above.

4/24

**Figure 4**

INSP037 (IPAAA44548) Cloned sequence with translation

```
1  GCATCAACAA CATCCAGTAA AACATGACTT CACCAAACGA ACTAAATAAG CTGCCATGGA CCAATCCTGG
      m t s p n e l n k l p w t n p
71  AGAAACAGAG ATATGTGACC TTTCAGACAC AGAATTCAAA ATATCTGTGT TGAAGAACCT CAAGGAAATT
      g e t e i c d l s d t e f k i s v l k n l k e i
141 CAAGATAACA CAGAGAAGGA ATCCAGAATT CTATCAGACA AATATAAGAA ACAGATTGAA ATAATTAAAG
      q d n t e k e s r i l s d k y k k q i e i i k
211 GGAATCAAGC AGAAATCTG GAGTTGAGAA ATGCAGATGG CACACTT TAG AATG
      g n q a e i l e l r n a d g t l
```


5/24

**Figure 5****Map of PCRII-TOPO-IPAAA44548**

Molecule: pCRII-TOPO-IPAAA44548, 4214 bps DNA Circular  
 File Name: 13124.cm5  
 Description: Plasmid ID 13124

**Molecule Features:**

Type	Start	End	Name	Description
MARKER	239		SP6	
REGION	337	600		IPAAA44548 cloned sequence
GENE	577	341	C 44548 cds	
MARKER	670		C T7	
REGION	854	1268	f1 ori	
GENE	1602	2396	KanR	
GENE	2414	3274	AmpR	
REGION	3419	4092	pUC ori	



**6/24**


### Figure 6

### Map of expression vector pEAK12d

Molecule: pEAK12 d, 8760 bps DNA Circular  
File Name: pEAK12DEST.cm5  
Description: Mammalian cell expression vector (plasmid ID 11345)

## Molecule Features:

Type	Start	End	Name	Description
REGION	2	595		pmb-ori
GENE	596	1519	Amp	
REGION	1690	2795	EF-1alpha	
REGION	2703	2722		position of pEAK12F primer
REGION	2796	2845		MCS
MARKER	2855		attR1	
GENE	3256	3915	CmR	
GENE	4257	4562	ccdB	
MARKER	4603		C attR2	
REGION	4733	4733		MCS
REGION	4734	5162		poly A/splice
REGION	4819	4848	C	position of pEAK12R primer
GENE	5781	5163	C PUR	PUROMYCIN
REGION	6005	5782	C tK	tK promoter
REGION	6500	6006	C Ori P	
GENE	8552	6500	C EBNA-1	
REGION	8553	8752	sv40	



7/24

Figure 7


## Map of plasmid pDONR201

Molecule: pDONR201, 4470 bps DNA Circular  
File Name: pDONR201.cm5, dated 17 Oct 2002

Description: Gateway entry vector (Invitrogen)- plasmid ID# 13309

## Molecule Features:

Type	Start	End	Name
REGION	332	563	attP1
GENE	959	1264	ccdB
REGION	2513	2744	attP2
GENE	2868	3677	KanR
REGION	3794	4467	pUC ori



**8/24**


### Figure 8

### Map of expression vector pEAK12d-IPAAA44548-6HIS

Molecule: pEAK12d-IPAAA44548-6HIS, 7201 bps DNA Circular  
File Name: 11775.cm5  
Description: Mammalian cell Expression Construct

## Molecule Features:

Type	Start	End	Name	Description
REGION	2	595		pmb-ori
GENE	596	1519	Amp	
REGION	1690	2795	EF-1a	
REGION	2703	2722		peak12D-F primer
MARKER	2855		attB1	
GENE	2888	3139	IPAAA44548-6HIS	
MARKER	3155		attB2	
REGION	3175	3603	'A	poly A/splice
REGION	3289	3270	C	pEAK12D-R primer
GENE	4222	3604	C	PUROMYCIN
REGION	4446	4223	C tK	tK promoter
REGION	4941	4447	C Ori P	
GENE	6993	4941	C EBNA-1	
REGION	6994	7193	sv40	





**9/24**

### Figure 9

### Map of E.coli expression vector pDEST14

Molecule: pDEST14, 6422 bps DNA Circular


File Name: pDEST14.cm5, dated 17 Oct 2002

Description: E.coli expressssion vector (Invitrogen)

Notes: Gateway compatible, Expression under control of T7 promoter

## Molecule Features:

Type	Start	End	Name	Description
MARKER	21		T7	Promoter
REGION	67	191	attR1	
GENE	441	1100	CmR	
GENE	1442	1747	ccdB	
REGION	1788	1912	attR2	
REGION	1964	1944	C	pDEST14 R primer
GENE	2638	3498	AmpR	
REGION	3643	4316	pBR322 ori	



10/24


Figure 10

## Map of plasmid pDEST14-IPAAA44548-6HIS

Molecule: pDEST14-IPAAA44548-6HIS, 4899 bps DNA Circular  
 File Name: 12896.cm5  
 Description: plasmid ID 12896

## Molecule Features:

Type	Start	End	Name	Description
MARKER	21		T7	
REGION	72	67 C	attB1	
REGION	94	108		Shine Dalgarno Sequence
GENE	109	360	IPAAA44548-6HIS	
REGION	376	389	attB2	
REGION	441	421 C		pDEST14-R primer
GENE	1115	1975	Amp	
REGION	2124	2763	ori	pBR322 ori



11/24

Figure 11

## PCRII TOPO IPAAA44548

1 AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC  
61 ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC  
121 TCACTCATTG GGCACCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA  
181 TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTAT  
241 TTAGGTGACA CTATAGAATA CTCAAGCTAT GCATCAAGCT TGGTACCGAG CTCGGATCCA  
301 CTAGTAACGG CCGCCAGTGT GCTGGAATTC GCCCTTCATT CTAAAGTGTG CCATCTGCAT  
361 TTCTCAACTC CAGAATTTCT GCTTGATTCC CTTTAATTAT TTCAATCTGT TTCTTATATT  
421 TGTCTGATAG AATTCTGGAT TCCTTCTCTG TGTATCTTG AATTCCTTG AGGTCTTCA  
481 ACACAGATAT TTTGAATTCT GTGTCTGAAA GGTACATAT CTCTGTTTCT CCAGGATTGG  
541 TCCATGGCAG CTTATTTAGT TCGTTTGGTG AAGTCATGTT TTAAGTGGATG TTGTGTGATG  
601 AAGGGCGAAT TCTGCAGATA TCCATCACAC TGGCGGCCGC TCGAGCATGC ATCTAGAGGG  
661 CCCAATTCGC CCTATAGTGA GTCGTATTAC AATTCAGTGG CCGTCGTTTT ACAACGTCGT  
721 GACTGGGAAA ACCCTGGCGT TACCCAACTT AATCGCCTTG CAGCACATCC CCCTTTCGCC  
781 AGCTGGCGTA ATAGCGAAGA GGCCGCACC GATCGCCCTT CCCAACAGTT GCGCAGCCTG  
841 AATGGCGAAT GGGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG  
901 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT  
961 TCCTTTCTCG CCACGTTTCG CGGCTTTCCC CGTCAAGCTC TAAATCGGGG GCTCCCTTTA  
1021 GGGTTCCGAT TTAGAGCTTT ACGGCACCTC GACCGCAAAA AACTTGATTT GGGTGATGGT  
1081 TCACGTAGTG GGCCATCGCC CTGATAGACG GTTTTTTCGCC CTTTGACGTT GGAGTCCACG  
1141 TTCTTTAATA GTGGACTCTT GTTCCAACT GGAACAACAC TCAACCCTAT CGCGGTCTAT  
1201 TCTTTTGATT TATAAGGGAT TTTGCCGATT TCGGCCTATT GGTAAAAAA TGAGCTGATT  
1261 TAACAAATTC AGGGCGCAAG GGCTGCTAAA GGAACCGGAA CACGTAGAAA GCCAGTCCGC  
1321 AGAAACGGTG CTGACCCCGG ATGAATGTCA GCTACTGGGC TATCTGGACA AGGGAAAACG  
1381 CAAGCGCAAA GAGAAAGCAG GTAGCTTGCA GTGGGCTTAC ATGGCGATAG CTAGACTGGG  
1441 CGGTTTTATG GACAGCAAGC GAACCGGAAT TGCCAGCTGG GGCGCCCTCT GGTAAGGTTG

12/24

1501 GGAAGCCCTG CAAAGTAAAC TGGATGGCTT TCTTGCCGCC AAGGATCTGA TGGCGCAGGG  
1561 GATCAAGATC TGATCAAGAG ACAGGATGAG GATCGTTTCG CATGATTGAA CAAGATGGAT  
1621 TGCACGCAGG TTCTCCGGCC GCTTGGGTGG AGAGGCTATT CGGCTATGAC TGGGCACAAC  
1681 AGACAATCGG CTGCTCTGAT GCCGCCGTGT TCCGGCTGTC AGCGCAGGGG CGCCCGGTTC  
1741 TTTTGTCAA GACCGACCTG TCCGGTGCCC TGAATGAACT GCAGGACGAG GCAGCGCGGC  
1801 TATCGTGGCT GGCCACGACG GGC GTTCCTT GCGCAGCTGT GCTCGACGTT GTCACTGAAG  
1861 CGGGAAGGGA CTGGCTGCTA TTGGGCGAAG TGCCGGGGCA GGATCTCCTG TCATCTCGCC  
1921 TTGCTCCTGC CGAGAAAGTA TCCATCATGG CTGATGCAAT GCGGCGGCTG CATACGCTTG  
1981 ATCCGGCTAC CTGCCCATTG GACCACCAAG CGAAACATCG CATCGAGCGA GCACGTACTC  
2041 GGATGGAAGC CGGTCTTGTC GATCAGGATG ATCTGGACGA AGAGCATCAG GGGCTCGCGC  
2101 CAGCCGAACT GTTCGCCAGG CTCAAGGCGC GCATGCCCGA CGGCGAGGAT CTCGTCTGTA  
2161 TCCATGGCGA TGCCCTGCTT CCGAATATCA TGGTGGAAAA TGGCCGCTTT TCTGGATTCA  
2221 ACGACTGTGG CCGGCTGGGT GTGGCGGACC GCTATCAGGA CATAGCGTTG GATACCCGTG  
2281 ATATTGCTGA AGAGCTTGGC GGC GAATGGG CTGACCGCTT CCTCGTGCTT TACGGTATCG  
2341 CCGCTCCCGA TTCGACGCGC ATCGCCTTCT ATCGCCTTCT TGACGAGTTC TTCTGAATTG  
2401 AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTGCGC CTTATTCCCT TTTTTCGGGC  
2461 ATTTTGCTT CCTGTTTTTG CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA  
2521 TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA  
2581 GAGTTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC TGCTATGTGA  
2641 TACACTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC GGTCGCCGCA TACACTATTG  
2701 TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG CATCTTACGG ATGGCATGAC  
2761 AGTAAGAGAA TTATGCAGTG CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT  
2821 TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA  
2881 TGTAACTCGC CTTGATCGTT GCGAACC GGA GCTGAATGAA GCCATACCAA ACGACGAGAG  
2941 TGACACCACG ATGCCTGTAG CAATGCCAAC AACGTTGCGC AAACCTATTAA CTGGCGAACT  
3001 ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGAATG GAGGCGGATA AAGTTGCAGG  
3061 ACCACTTCTG CGCTCGGCCC TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG

13/24

3121 TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC GCTCCCGTAT  
3181 CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA GACAGATCGC  
3241 TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACGTCA GACCAAGTTT ACTCATATAT  
3301 ACTTTAGATT GATTTAAAAC TTCATTTTTA ATTTAAAAGG ATCTAGGTGA AGATCCTTTT  
3361 TGATAATCTC ATGACCAAAA TCCCTTAACG TGAGTTTTTCG TTCCACTGAG CGTCAGACCC  
3421 CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT  
3481 GCAAACAAAA AAACCACCGC TACCAGCGGT GGTGTGTTG CCGGATCAAG AGCTACCAAC  
3541 TCTTTTTCCG AAGGTAAGT GCTTCAGCAG AGCGCAGATA CCAAATACTG TCCTTCTAGT  
3601 GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA CCGCCTACAT ACCTCGCTCT  
3661 GCTAATCCTG TTACCAGTGG CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA  
3721 CTCAAGACGA TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC  
3781 ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC GTGAGCTATG  
3841 AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG TATCCGGTAA GCGGCAGGGT  
3901 CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAAC GCCTGGTATC TTTATAGTCC  
3961 TGTCGGGTTT CGCCACCTCT GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG  
4021 GAGCCTATGG AAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGGCT TTTGCTGGCC  
4081 TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC GTATTACCGC  
4141 CTTTGAGTGA GCTGATACCG CTCGCCGAG CCGAACGACC GAGCGCAGCG AGTCAGTGAG  
4201 CGAGGAAGCG GAAG

14/24

Figure 12

## pDEST14-IPAAA44548-6HIS

1 AGATCTCGAT CCCGCGAAAT TAATACGACT CACTATAGGG AGACCACAAC GGTTTCCCTC TAGATCACAA GTTTGTACAA  
81 AAAAGCAGGC TTCGAAGGAG ATATACATAT GACTTCACCA AACGAACTAA ATAAGCTGCC ATGGACCAAT CCTGGAGAAA  
161 CAGAGATATG TGACCTTTCA GACACAGAAT TCAAAATATC TGTGTTGAAG AACCTCAAGG AAATTCAAGA TAACACAGAG  
241 AAGGAATCCA GAATTCTATC AGACAAATAT AAGAAACAGA TTGAAATAAT TAAAGGGAAT CAAGCAGAAA TTCTGGAGTT  
321 GAGAAATGCA GATGGCACAC TTCACCATCA CCATCACCAT TGAAACCCAG CTTTCTTGTA CAAAGTGGTG ATGATCCGGC  
401 TGCTAACAAA GCCCCGAAAG AAGCTGAGTT GGCTGCTGCC ACCGCTGAGC AATAACTAGC ATAACCCCTT GGGGCCCTCTA  
481 AACGGGTCTT GAGGGGTTTT TTGCTGAAAG GAGGAACTAT ATCCGGATAT CCACAGGACG GGTGTGGTCG CCATGATCGC  
561 GTAGTCGATA GTGGCTCCAA GTAGCGAAGC GAGCAGGACT GGGCGGCGGC CAAAGCGGTC GGACAGTGCT CCGAGAACGG  
641 GTGCGCATAG AAATTGCATC AACGCATATA GCGCTAGCAG CACGCCATAG TGAAGTGGCA TGCTGTCGGA ATGGACGATA  
721 TCCCCGAAGA GGGCCGGCAG TACCGGCATA ACCAAGCCTA TGCCTACAGC ATCCAGGGTG ACGGTGCCGA GGATGACGAT  
801 GAGCGCATTG TTAGATTTCA TACACGGTGC CTGACTGCGT TAGCAATTTA ACTGTGATAA ACTACCGCAT TAAAGCTTAT  
881 CGATGATAAG CTGTCAAACA TGAGAATTCT TGAAGACGAA AGGGCCTCGT GATACGCCTA TTTTATAGG TTAATGTCAT  
961 GATAATAATG GTTTCTTAGA CGTCAGGTGG CACTTTTCGG GGAAATGTGC GCGGAACCCC TATTTGTTTA TTTTCTTAAA  
1041 TACATTCAAA TATGTATCCG CTCATGAGAC AATAACCCCTG ATAAATGCTT CAATAATATT GAAAAGGAA GAGTATGAGT  
1121 ATTCAACATT TCCGTGTCGC CCTTATTCCT TTTTTCGCGG CATTTTGCCT TCCTGTTTTT GCTCACCAG AAACGCTGGT  
1201 GAAAGTAAAA GATGCTGAAG ATCAGTTGGG TGCACGAGTG GGTACATCG AACTGGATCT CAACAGCGGT AAGATCCTTG  
1281 AGAGTTTTCG CCCCAGAGAA CGTTTTCCAA TGATGAGCAC TTTTAAAGTT CTGCTATGTG GCGCGGTATT ATCCCGTGTT  
1361 GACGCCGGGC AAGAGCAACT CGGTCGCCGC ATACACTATT CTCAGAATGA CTTGGTTGAG TACTCACCAG TCACAGAAAA  
1441 GCATCTTACG GATGGCATGA CAGTAAGAGA ATTATGCAGT GCTGCCATAA CCATGAGTGA TAACACTGCG GCCAACTTAC  
1521 TTCTGACAAC GATCGGAGGA CCGAAGGAGC TAACCGCTTT TTTGCACAAC ATGGGGGATC ATGTAAGTGC CCTTGATCGT  
1601 TGGGAACCGG AGCTGAATGA AGCCATACCA AACGACGAGC GTGACACCAC GATGCCTGCA GCAATGGCAA CAACGTTGCG  
1681 CAACTATTA ACTGGCGAAC TACTTACTCT AGCTTCCCGG CAACAATTAA TAGACTGGAT GGAGGCGGAT AAAGTGCAG  
1761 GACCACTTCT GCGCTCGGCC CTTCCGGCTG GCTGTTTTAT TGCTGATAAA TCTGGAGCCG GTGAGCGTGG GTCTCGCGGT  
1841 ATCATTGCAG CACTGGGGCC AGATGGTAAG CCCTCCCGTA TCGTAGTTAT CTACACGACG GGGAGTCAGG CAACTATGGA  
1921 TGAACGAAAT AGACAGATCG CTGAGATAGG TGCCTCACTG ATTAAGCATT GGTAAGTGC AGACCAAGTT TACTCATATA  
2001 TACTTTAGAT TGATTAAAA CTTCATTTTT AATTTAAAG GATCTAGGTG AAGATCCTTT TTGATAATCT CATGACCAAA  
2081 ATCCCTTAAC GTGAGTTTTT GTTCCACTGA GCGTCAGACC CCGTAGAAAA GATCAAAGGA TCTTCTTGAG ATCCTTTTTT  
2161 TCTGCGCGTA ATCTGCTGCT TGCAAACAAA AAAACCACCG CTACCAGCGG TGGTTTGTGTT GCCGGATCAA GAGCTACCAA  
2241 CTCCTTTTCC GAAGTAACT GGCTTCAGCA GAGCGCAGAT ACCAAATACT GTCCTTCTAG TGAGCCGTA GTTAGGCCAC  
2321 CACTTCAAGA ACTCTGTAGC ACCGCCTACA TACCTCGCTC TGCTAATCCT GTTACCAGTG GCTGCTGCCA GTGGCGATAA

2401 GTCGTGCTCTT ACCGGGTGG ACTCAAGACG ATAGTTACCG GATAAGGCGC AGCGGTCTGG CTGAACGGGG GTTCGTGCA  
2481 CACAGCCCAG CTGGAGCGA ACGACCTACA CGAACTGAG ATACCTACAG CGTGAGCTAT GAGAAAGCGC CACGCTTCCC  
2561 GAAGGGAGAA AGGCGGACAG GTATCCGGTA AGCGGCAGGG TCGGAACAGG AGAGCGCACG AGGGAGCTTC CAGGGGGAAA  
2641 CGCCTGGTAT CTTTATAGTC CTGTCGGGTT TCGCCACCTC TGACTTGAGC GTCGATTTT GTGATGCTCG TCAGGGGGGC  
2721 GGAGCCTATG GAAAACGCC AGCAACGCGG CCTTTTACG GTTCCTGGCC TTTTGCTGGC CTTTGTCTCA CATGTTCTTT  
2801 CCTGCGTTAT CCCCTGATTC TGTGGATAAC CGTATTACCG CCTTTGAGTG AGCTGATACC GCTCGCCGCA GCCGAACGAC  
2881 CGAGCGCAGC GAGTCAGTGA GCGAGGAAGC GGAAGAGCGC CTGATGCGGT ATTTTCTCCT TACGCATCTG TCGGGTATTT  
2961 CACACCGCAT ATATGGTGCA CTCTCAGTAC AATCTGCTCT GATGCCGCAT AGTTAAGCCA GTATACACTC CGCTATCGCT  
3041 ACGTGACTGG GTCATGGCTG CGCCCCGACA CCCGCCAACA CCCGCTGACG CGCCCTGACG GGCTTGCTCTG CTCCCGGCAT  
3121 CCGCTTACAG ACAAGCTGTG ACCGTCCTCG GGAGCTGCAT GTGTGAGAGG TTTTCACCGT CATCACCGAA ACGCGCGAGG  
3201 CAGCTGCGGT AAAGCTCATC AGCGTGGTCG TGAAGCGATT CACAGATGTC TGCCGTGTCA TCCGCGTCCA GCTCGTTGAG  
3281 TTTCTCCAGA AGCGTTAATG TCTGGCTTCT GATAAAGCGG GCCATGTTAA GGGCGGTTTT TTCCTGTTTG GTCAGTATG  
3361 CCTCCGTGTA AGGGGATTT CTGTTTCATGG GGGTAATGAT ACCGATGAAA CGAGAGAGGA TGCTCACGAT ACGGGTTACT  
3441 GATGATGAAC ATGCCCGTT ACTGGAACGT TGTGAGGGTA AACAACTGGC GGTATGGATG CGGCGGGACC AGAGAAAAAT  
3521 CACTCAGGGT CAATGCCAGC GCTTCGTAA TACAGATGTA GGTGTTCAC AGGGTAGCCA GCAGCATCCT GCGATGCAGA  
3601 TCCGAACAT AATGGTGAG GCGCTGACT TCCGCGTTTC CAGACTTTAC GAAACACGGA AACCGAAGAC CATTCATGTT  
3681 GTTGCTCAGG TCGCAGACGT TTTGAGCAG CAGTCGCTTC ACGTTGCTC GCGTATCGGT GATTCATTCT GCTAACCAGT  
3761 AAGGCAACCC CGCCAGCCTA GCCGGTCTCT CAACGACAGG AGCAGATCA TCGCACCCG TGGCCAGGAC CCAACGCTGC  
3841 CCGAGATGCG CCGCGTGGG CTGCTGGAGA TGGCGGACGC GATGGATATG TTCTGCCAAG GGTGGTTTG CGCATTACA  
3921 GTTCTCCGA AGAATTGATT GGCTCCAATT CTTGGAGTGG TGAATCCGTT AGCGAGGTGC CGCCGGCTTC CATTAGGTC  
4001 GAGGTGGCCC GGCTCCATGC ACCGCGACGC AACGCGGGGA GGCAGACAAG GTATAGGGCG GCGCCTACAA TCCATGCCAA  
4081 CCCGTTCAT GTGCTCGCCG AGGCGGCATA AATCGCCGTG ACGATCAGCG GTCCAGTGAT CGAAGTTAGG CTGGTAAGAG  
4161 CCGCGAGCGA TCCTGAAGC TGTCCCTGAT GGTGCTCATC TACCTGCCTG GACAGCATGG CCTGCAACGC GGGCATCCCC  
4241 ATGCCCGCGG AAGCGAGAAG AATCATAATG GGAAGGCCA TCCAGCCTCG GTCGCGAAC GCCAGCAAGA CGTAGCCAG  
4321 CGCGTCGGCC GCCATGCCGG CGATAATGGC CTGCTTCTCG CCGAAACGTT TGGTGGCGGG ACCAGTGACG AAGGCTTGAG  
4401 CGAGGGCGTG CAAGATTCG AATACCGCAA GCGACAGGCC GATCATCGTC GCGCTCCAGC GAAAGCGGTC CTCGCCGAAA  
4481 ATGACCCAGA GCGCTGCCGG CACCTGTCCT ACGAGTTGCA TGATAAAGAA GACAGTCATA AGTGCGGCGA CGATAGTCAT  
4561 GCCCCGCGCC CACCGGAAGG AGCTGACTGG GTTGAAGGCT CTCGAAGGCA TCGGTGATC GACGCTCTCC CTTATGCGAC  
4641 TCCTGCATTA GGAAGCAGCC CAGTAGTAGG TTGAGGCCGT TGAGCACCAG CGCCGCAAGG AATGGTGAT GCAAGGAGAT  
4721 GGCGCCCAAC AGTCCCCCG CCACGGGGCC TGCCACCATA CCCACGCCGA AACAAAGCGCT CATGAGCCCG AAGTGGCGAG  
4801 CCCGATCTTC CCCATCGGTG ATGTCGGCGA TATAGGCGCC AGCAACCGCA CCTGTGGCGC CGGTGATGCC GGCCACGATG  
4881 CGTCCGGCGT AGAGGATCG

Figure 13

## pEAK12D-IPAAA44548-6HIS

1 GCGGTAATCT GCTGCTTGCA AACAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT  
81 TTTTCCGAAG GTAACGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC TTCTAGTGTA GCCGTAGTTA GGCCACCACT  
161 TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT GAAGCCAGTT ACCAGTGGCT GCTGCCAGTG GCGATAAGTC  
241 GTGTCTTACC GGGTTGGACT CAAGAGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA  
321 GCCCAGCTTG GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG  
401 GGAGAAAGGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC  
481 TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTGTGA TGCTCGTCAG GGGGGCGGAG  
561 CCTATGGAAA AACGCCAGCA ACGCAAGCTA GAGTTTAAAC TTGACAGATG AGACAATAAC CCTGATAAAT GCTTCAATAA  
641 TATTGAAAAA GGAAGGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT  
721 TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCA GAAGATCACT TGGGTGCGCG AGTGGGTAC ATCGAACTGG  
801 ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTC CCAATGATGA GCACTTTTAA AGTCTGCTA  
881 TGTGGCGCGG TATTATCCCG TATTGATGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA ATGACTTGGT  
961 TGAATACTCA CAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA  
1041 GTGATAACAC TCGGGCCAAC TTACTTCTGA CAACTATCGG AGGACCGAAG GAGCTAACCG CTTTTTGA CAACATGGGG  
1121 GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC  
1201 TGTAGCAATG GCAACAACGT TCGGAAAAC ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA CTAATAGACT  
1281 GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCACCTCCG GCTGGCTGGT TTATTGCTGA TAAATCAGGA  
1361 GCCGGTGAGC GTGGGTCAG CGGTATCATT GCAGCACTGG GGCCGGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC  
1441 TACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAG  
1521 GATAAATTTT TGGAAGGAG GACACGTATG GAAGTGGGCA AGTTGGGGAA GCCGTATCCG TTGCTGAATC TGGCATATGT  
1601 GGGAGTATAA GACGCGCAGC GTCGCATCAG GCATTTTTTT CTGCGCCAAT GCAAAAAGGC CATCCGTCAG GATGGCCTTT  
1681 CGGCATAACT AGTGAGGCTC CGGTGCCCGT CAGTGGGCAG AGCGCACATC GCCCACAGTC CCCGAGAAGT TGGGGGAGG  
1761 GGTGCGCAAT TGAACCGGTG CTTAGAGAAG GTGGCGCGGG GTAAACTGGG AAAGTGATGT CGTGTACTGG CTCGCTTTT  
1841 TTCCCGAGGG TGGGGGAGAA CCGTATATAA GTGCAGTAGT CGCCGTGAAC GTTCTTTTTC GCAACGGGTT TGCCGCCAGA  
1921 ACACAGGTAA GTGCCGTGTG TGGTTCCCGC GGGCCTGGCC TCTTTACGGG TTATGGCCCT TGCGTGCCTT GAATTACTTC  
2001 CACCTGGCTG CAGTACGTGA TTCTTGATCC CGAGCTTCGG GTTGGAAGTG GGTGGGAGAG TTCGAGGCC TCGCTTAAG  
2081 GAGCCCTTTC GCCTCGTGCT TGAGTTGAGG CCTGGCCTGG GCGCTGGGGC CGCCGCGTGC GAATCTGGTG GCACCTTCGC  
2161 GCCTGTCTCG CTGCTTTCGA TAAGTCTCTA GCCATTTAAA ATTTTGTATG ACCTGCTGCG ACGCTTTTTT TCTGGCAAGA



2241 TAGTCTTGTA AATGCGGGCC AAGACGATCT GCACACTGGT ATTTCGGTTT TTGGGGCCGC GGGCGGCGAC GGGGCCCGTG  
2321 CGTCCCAGCG CACATGCATG TTCGGCGAGG CGGGGCCTGC GAGCGCGGCC ACCGAGAATC GGACGGGGGT AGTCTCAAGC  
2401 TGGCCGGCCT GCTCTGGTGC CTGGCCTCGC GCCGCCGTGT ATCGCCCCGC CCTGGGCGGC AAGGCTGGGA GCTCAAAATG  
2481 GAGGACGCGG CGCTCGGGAG AGCGGGCGGG TGAGTCACCC ACACAAAGGA AAAGGGCCTT TCCGTCTCTCA GCCGTCGCTT  
2561 CATGTGACTC CACGGAGTAC CGGGCGCCGT CCAGGCACCT CGATTAGTTC TCGAGCTTTT GGAGTACGTC GTCTTTAGGT  
2641 TGGGGGGAGG GGTTTTATGC GATGGAGTTT CCCACACTG AGTGGGTGGA GACTGAAGTT AGGCCAGCTT GGCACCTGAT  
2721 GTAATTCTCC TTGGAATTTG CCCTTTTGA GTTTGGATCT TGGTTCATTC TCAAGCCTCA GACAGTGGTT CAAATTAATA  
2801 CGACTCACTA TAGGGAGACT TCTTCTCCC ATTTCAAGTG TCGTAAGCTA TCAAACAAGT TTGTACAAA .AAGCAGGCTT  
2881 CGCCACCATG ACTTCACCAA ACGAACTAAA TAAGCTGCCA TGGACCAATC CTGGAGAAAC AGAGATATGT GACCTTTCAG  
2961 ACACAGAATT CAAAATATCT GTGTTGAAGA ACCTCAAGGA AATTCAAGAT AACACAGAGA AGGAATCCAG AATTCTATCA  
3041 GACAAATATA AGAAACAGAT TGAAATAATT AAAGGGAATC AAGCAGAAAT TCTGGAGTTG AGAAATGCAG ATGGCACACT  
3121 TCACCATCAC CATCACCATT GAAACCCAGC TTTCTGTAC AAAGTGGTTC GATGGCCGCA GGTAAGCCAG CCCAGGCCTC  
3201 GCCCTCCAGC TCAAGGCGGG ACAGGTGCCC TAGAGTAGCC TGCATCCAGG GACAGGCCCC AGCCGGGTGC TGACACGTCC  
3281 ACCTCCATCT CTTCCTCAGG TCTGCCCGGG TGGCATCCCT GTGACCCCTC CCCAGTGCCT CTCCTGGTCG TGAAGGTGC  
3361 TACTCCAGTG CCCACCAGCC TTGTCTAAT AAAATTAAGT TGCATCATTT TGTTTGACTA GGTGTCCTTG TATAATATTA  
3441 TGGGGTGGAG GCGGGTGGA TGGAGCAAGG GGCCCAAGTT AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA  
3521 ATAGCATCAC AAATTTACACA AATAAAGCAT TTTTTCCTACT GCATTCTAGT TGTGGTTTGT CCAAACCTCAT CAATGTATCT  
3601 TATCATGTCT GGATCCGCTT CAGGCACCGG GCTTGCGGGT CATGCACCAG GTGCGCGGTC CTTCGGGCAC CTCGACGTGC  
3681 GCGGTGACGG TGAAGCCGAG CCGCTCGTAG AAGGGGAGGT TGCGGGGCGC GGAGGTCTCC AGGAAGGCGG GCACCCCGGC  
3761 GCGCTCGGCC GCCTCCACTC CGGGGAGCAC GACGGCGCTG CCCAGACCCT TGCCCTGGTG GTCGGGCGAG ACGCCGACGG  
3841 TGGCCAGGAA CCACGCGGC TCCTTGGGCC GGTGCGGCGC CAGGAGGCCT TCCATCTGTT GCTGCGCGGC CAGCCTGGAA  
3921 CCGCTCAACT CGGCCATGCG CGGGCGATC TCGGCGAACA CCGCCCCGC TTCGACGCTC TCCGGCGTGG TCCAGACCGC  
4001 CACCGCGGCG CCGTCGTCCG CGACCCACAC CTTGCGGATG TCGAGCCCGA CGCGCGTGAG GAAGAGTTCT TGCAGCTCGG  
4081 TGACCCGCTC GATGTGGCGG TCCGGGTCGA CGGTGTGGCG CGTGGCGGG TAGTCGGCGA ACGCGGCGGC GAGGGTGGCT  
4161 ACGGCCCCGG GGACGTCGTC GCGGGTGGCG AGGCGCACCG TGGGCTTGTA CTCGGTCATG GTGGCCTGCA GAGTCGCTCT  
4241 GTGTTGAGG CCACACGCGT CACCTTAATA TGCGAAGTGG ACCTGGGACC GCGCCGCCCC GACTGCATCT GCGTGTTTTC  
4321 GCCAATGACA AGACGCTGGG CGGGGTTTGT GTCATCATAG AACTAAAGAC ATGCAAATAT ATTTCTTCCG GGGACACCGC  
4401 CAGCAAACGC GAGCAACGGG CCACGGGGAT GAAGCAGCTG CGCCACTCCC TGAAGATCCC CCTTATTAAC CCTAAACGGG  
4481 TAGCATATGC TTCCCGGGTA GTAGTATATA CTATCCAGAC TAACCCTAAT TCAATAGCAT ATGTTACCCA ACGGGAAGCA  
4561 TATGCTATCG AATTAGGGTT AGTAAAAGG TCCTAAGGAA CAGCGATCTG GATAGCATAT GCTATCCTAA TCTATATCTG  
4641 GGTAGCATAT GCTATCCTAA TCTATATCTG GGTAGCATAG GCTATCCTAA TCTATATCTG GGTAGCATAT GCTATCCTAA  
4721 TCTATATCTG GGTAGTATAT GCTATCCTAA TTTATATCTG GGTAGCATAG GCTATCCTAA TCTATATCTG GGTAGCATAT

18/24

4801 GCTATCCTAA TCTATATCTG GGTAGTATAT GCTATCCTAA TCTGTATCCG GGTAGCATAT GCTATCCTCA TGCATATACA  
4881 GTCAGCATAT GATACCCAGT AGTAGAGTGG GAGTGCTATC CTTTGCATAT GCCGCCACCT CCCAAGGAGA TCCGCATGTC  
4961 TGATTGCTCA CCAGGTAAAT GTCGCTAATG TTTTCCAACG CGAGAAGGTG TTGAGCGCGG AGCTGAGTGA CGTGACAACA  
5041 TGGGTATGCC CAATTGCCCC ATGTTGGGAG GACGAAAATG GTGACAAGAC AGATGGCCAG AAATACACCA ACAGCACGCA  
5121 TGATGTCTAC TGGGGATTTA TTCTTTAGTG CGGGGAATA CACGGCTTTT AATACGATTG AGGGCGTCTC CTAACAAGTT  
5201 ACATCACTCC TGCCCTTCCT CACCCTCATC TCCATCACCT CCTTCATCTC CGTCATCTCC GTCATCACCC TCCGCGGCAG  
5281 CCCCTTCCAC CATAGGTGGA AACCAGGGAG GCAAATCTAC TCCATCGTCA AAGCTGCACA CAGTCACCCT GATATTGCAG  
5361 GTAGGAGCGG GCTTTGTCTAT AACAAAGTCC TTAATCGCAT CCTTCAAAC CTCAGCAAAT ATATGAGTTT GTAAAAAGAC  
5441 CATGAAATAA CAGACAATGG ACTCCCTTAG CGGGCCAGGT TGTGGGCCGG GTCCAGGGGC CATTCCAAAG GGGAGACGAC  
5521 TCAATGGTGT AAGACGACAT TGTGGAATAG CAAGGGCAGT TCCTCGCCTT AGGTTGTAAA GGGAGGTCTT ACTACCTCCA  
5601 TATACGAACA CACCGGCGAC CCAAGTTCCT TCGTCGGTAG TCCTTTCTAC GTGACTCCTA GCCAGGAGAG CTCTTAAACC  
5681 TTCTGCAATG TTCTCAAATT TCGGGTTGGA ACCTCCTTGA CCACGATGCT TTCCAAACCA CCCTCCTTTT TTGCGCCTGC  
5761 CTCCATCACC CTGACCCCGG GGTCCAGTGC TTGGGCCTTC TCCTGGGTCA TCTGCGGGGC CCTGCTCTAT CGCTCCCGGG  
5841 GGCACGTCAG GCTCACCATC TGGGCCACCT TCTTGGTGGT ATTCAAATA ATCGGCTTCC CCTACAGGTG GGAATAATGG  
5921 CCTTCTACCT GGAGGGGGCC TGCGCGGTGG AGACCCGGAT GATGATGACT GACTACTGGG ACTCCTGGGC CTCTTTTCTC  
6001 CACGTCCACG ACCTCTCCCC CTGGCTCTTT CACGACTTCC CCCCCTGGCT CTTTCACGTC CTCTACCCCG GCGGCCCTCA  
6081 CTACCTCCTC GACCCCGGCC TCCACTACCT CCTCGACCCC GGCCTCCACT GCCTCCTCGA CCCCAGCCTC CGGCACCTCC  
6161 TCCAGCCCCA GCACCTCCAC CAGCCCCAGC TCCCCAGCT CCAGCCCCAC CAGCACCAGC CCCTCCAGCC CCACCAGCCC  
6241 CAGCCCCCTC GGCACCTCCT CCAGCCCCAG CACCTCCACC AGCCCCAGCT CCCCAGCTC CAGCCCCACC AGCACCAGCC  
6321 CCTCCAGCCC CACCAGCCCC AGCCCTCCT GTTCCACCGT GGGTCCCTTT GCAGCCAATG CAACTTGGAC GTTTTGGGG  
6401 TCTCCGACA CCATCTCTAT GTCTTGGCCC TGATCCTGAG CCGCCCGGGG CTCCTGGTCT TCCGCTCCTC CGTCTCGTC  
6481 CTCTTCCCG TCCTCGTCCA TGGTTATCAC CCCCTCTTCT TTGAGGTCCA CTGCGCCGG AGCCTTCTGG TCCAGATGTG  
6561 TCTCCCTTCT CTCCTAGGCC ATTTCCAGGT CCTGTACCTG GCCCCTCGTC AGACATGATT CAACTAAAA GAGATCAATA  
6641 GACATCTTTA TTAGACGACG CTCAGTGAAT ACAGGGAGTG CAGACTCCTG CCCCCTCAA CAGCCCCCCC ACCCTCATCC  
6721 CCTTCATGGT CGCTGTCAGA CAGATCCAGG TCTGAAAATT CCCCATCCTC CGAACCATCC TCGTCTCAT CACCAATTAC  
6801 TCGCAGCCCG GAAAACTCCC GCTGAACATC CTCAGATTTT GCGTCCTGAG CCTCAAGCCA GGCCTCAAAT TCCTCGTCCC  
6881 CCTTTTGCT GGACGGTAGG GATGGGGATT CTCGGGACCC CTCCTCTTCC TCTTCAAGGT CACCAGACAG AGATGCTACT  
6961 GGGGCAACGG AAGAAAAGCT GGGTGGCGCC TGTGAAGCTA AGATCTGTG ACATCGATGG GCGCGGGTGT AACTCCGCC  
7041 CATCCCGCCC CTAATCCGC CCAGTTCGC CCATCTCCG CCTCATGGCT GACTAATTTT TTTTATTAT GCAGAGGCCG  
7121 AGGCCGCTC GGCCTCTGAG CTATTCAGA AGTAGTGAG AGGCTTTTTT GGAGGCTAG GCTTTTGCAA AAAGCTAATT  
7201 C

19/24

**Figure 14****BLASTP v NCBI nr**

Query= INSP037.pep  
(78 letters)

Database: All non-redundant GenBank CDS  
translations+PDB+SwissProt+PIR+PRF  
1,446,218 sequences; 465,230,387 total letters

Searching.....done

	Score	E
Sequences producing significant alignments:	(bits)	Value
ref XP_211857.1  hypothetical protein XP_211857 [Homo sapiens]	109	8e-24
ref XP_112161.2  similar to putative RNA binding protein 1 [Ratt...	38	0.041
ref XP_220945.1  similar to keratin 21, type I, cytoskeletal - r...	37	0.069
ref NP_775151.1  cytokeratin 21 [Rattus norvegicus] >gi 125089 s...	37	0.069
gb AAD49229.2 AF159462_1 EHEC factor for adherence [Escherichia ...	35	0.26
gb AAL57562.1 AF453441_46 Efa1 [Escherichia coli]	35	0.26
emb CAB55629.1  lymphostatin [Escherichia coli]	35	0.26
emb CAC81883.1  Efa1-LifA-Tox protein [Escherichia coli]	35	0.26
gb AAA39399.1  ORF1	35	0.34
pir  T36223 hypothetical protein SCE39.13c - Streptomyces coelic...	34	0.59
>ref XP_211857.1  hypothetical protein XP_211857 [Homo sapiens]		
Length = 113		

Score = 109 bits (273), Expect = 8e-24  
Identities = 54/74 (72%), Positives = 63/74 (84%)

Query: 1 MTSPNELNKLPTNPGETEICDLSDTEFKISVLKLNKEIQDNTESRILSDKYKKQIEI 60  
MTSPNELN+ P TNP ETEIC++ D EFKI+VL+ L EIQDNTKE ++LSDK K+IEI  
Sbjct: 1 MTSPNELNEAPGTNPAETEICNILDREFKIAVLRKLNEIQDNTKEKLVLSDKIIEIEI 60

Query: 61 IKGNAEILELRNA 74  
IK NQAEILEL+NA  
Sbjct: 61 IKMNQAEILELKNA 74

20/24

**Figure 15****BLAST v month-aa**

Query= INSP037.pep  
(78 letters)

Database: NCBI: Rolling month (30 days) of new/revised protein  
sequences

37,755 sequences; 14,558,446 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
ref XP_141262.1  similar to NAG14 protein [Homo sapiens] [Mus mu...	30	0.27
ref NP_831679.1  Phage-related protein [Bacteriophage phBC6A51] ...	30	0.36
ref NP_083191.1  RIKEN cDNA 1200008A14 [Mus musculus] >gi 128359...	29	0.61
ref NP_852012.1  neck appendage [Streptococcus phage C1] >gi 309...	28	0.80
ref NP_064648.1  neurexin I; neurexin I beta; neurexin I alpha; ...	28	1.0
ref XP_319358.1  ENSANGP00000006161 [Anopheles gambiae] >gi 2130...	28	1.0
ref XP_308412.1  ENSANGP00000019827 [Anopheles gambiae] >gi 2129...	28	1.0
ref NP_196806.2  expressed protein [Arabidopsis thaliana]	27	1.8
gb AAL29689.1  Snf2-related chromatin remodeling factor SRCAP [T...	27	1.8
ref XP_314825.1  ENSANGP00000011098 [Anopheles gambiae] >gi 2129...	27	1.8
ref XP_311503.1  ENSANGP00000013657 [Anopheles gambiae] >gi 2129...	27	2.3

>ref|XP\_141262.1| similar to NAG14 protein [Homo sapiens] [Mus musculus]  
 ref|XP\_230311.1| similar to NAG14 protein [Homo sapiens] [Rattus norvegicus]  
 ref|NP\_848840.1| RIKEN cDNA 6430556C10 gene [Mus musculus]  
 dbj|BAC28656.1| unnamed protein product [Mus musculus]  
 dbj|BAC33302.1| unnamed protein product [Mus musculus]  
 Length = 640

Score = 30.0 bits (66), Expect = 0.27

Identities = 22/59 (37%), Positives = 33/59 (55%), Gaps = 8/59 (13%)

Query: 20 ICDLSDTEFK-ISVLKNLKEIQDNTESRILSDKYKKQIEIIRGN-----QAEILEL 71  
 +C S+ K I V KNL+E+ D +R+L + ++ QI+IIK N EIL+L  
 Sbjct: 50 VCSCSNQFSKVICVRKNLREVPDGI STNTRLN-LNHNQIQIKVNSFKHLRHLLEILQL 107

21/24

## Figure 16A

## TBLASTN v NCBI nt-month

Query= INSP037.pep  
(78 letters)

Database: NCBI: Rolling month (30 days) of new/revised nt sequences  
(GenBank+ EMBL + DDBJ sequences (but no EST, STS, GSS, or phase 0, 1  
or 2 HTGS sequences))  
44,426 sequences; 216,324,491 total letters

Searching.....done

Sequences producing significant alignments:	Score (bits)	E Value
gb AC093724.3  Homo sapiens BAC clone RP11-1L5 from 2, complete ...	105	2e-23
emb BX510371.4  Human DNA sequence from clone RP13-728A10 on chr...	89	2e-18
gb AC144561.8  Homo sapiens 3 BAC RP11-628C23 (Roswell Park Canc...	82	4e-16
dbj AP001827.5  Homo sapiens genomic DNA, chromosome 11 clone:RP...	80	1e-15
emb Z97632.3 HS196E23 Human DNA sequence from clone RP1-196E23 o...	66	3e-11
emb BX322234.7  Human DNA sequence from clone XXYac-65C7_A on ch...	62	5e-10
dbj AP005138.3  Homo sapiens genomic DNA, chromosome 18 clone:RP...	54	1e-07
dbj AP006292.2  Homo sapiens genomic DNA, chromosome 9 clone:RP1...	54	1e-07
gb AC083903.10  Homo sapiens chromosome UNK clone RP11-785G23, c...	47	1e-05
gb AY293855.1  Homo sapiens insulin-like growth factor 2 recepto...	45	7e-05

>gb|AC093724.3| Homo sapiens BAC clone RP11-1L5 from 2, complete sequence  
Length = 161617

Score = 105 bits (263), Expect = 2e-23  
Identities = 55/78 (70%), Positives = 62/78 (78%)  
Frame = -3

Query: 1 MTSPNELNKL PWTNPGETEICDLS DTEFKISVLKLNKEIQDNTESRILSDKYKKQIEI 60  
MTSPNELNK P NP ET++CDLS EFKI+VL+ LKEIQDNT EK RILSDK+ K IEI  
Sbjct: 22538 MTSPNELNKAPRINPQETKLC DLSHGFEFKI AVLRLKLEIQDNT EKGFRILSDKFNKDIEI 22359

Query: 61 IKGNQAEILELRNADGTL 78  
I +AEILEL+NA G L  
Sbjct: 22358 IFKTRAEILELKNAGIL 22305

Score = 30.0 bits (66), Expect = 1.7  
Identities = 19/60 (31%), Positives = 35/60 (57%)  
Frame = +3

Query: 14 NPGETEICDLS DTEFKISVLKLNKEIQDNTESRILSDKYKKQIEI IKGNQAEILELRN 73  
+P + EI DLS+ EFK+ V+K ++E + E + + K +K I+ +KG + ++ N  
Sbjct: 111237 DPNKEITDLS EKEFKL-VIKLIREGPEKGEAQCK----KI QKVIQ\*VKGETFKEIDSLN 111401

22/24

**Figure 16B****TBLASTN v NCBI nt**

Query= INSP037.pep  
(78 letters)

Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, GSS,  
or phase 0, 1 or 2 HTGS sequences)

1,794,754 sequences; 8,367,844,792 total letters

Searching.....done

	Score	E
Sequences producing significant alignments:	(bits)	Value
gb AC112641.3  Homo sapiens 3 BAC RP11-431I8 (Roswell Park Cance...	158	2e-37
gb AC026118.17  Homo sapiens 3 BAC RP11-67F24 (Roswell Park Canc...	158	2e-37
emb AL020989.2 HS192P9 Human DNA sequence from clone RP1-192P9 o...	117	3e-25
gb AC009811.14  Homo sapiens chromosome 3, clone RP11-491K7, com...	116	7e-25
gb AC108166.5  Homo sapiens BAC clone RP11-724L20 from 4, comple...	115	9e-25
gb AC011299.3 AC011299 Homo sapiens BAC clone RP11-232C20 from 7...	115	1e-24
gb AC144613.1  Pan troglodytes chromosome 7 clone RP43-1F6, comp...	115	1e-24
dbj AP001992.4  Homo sapiens genomic DNA, chromosome 11q clone:R...	115	1e-24
emb AL359393.9  Human DNA sequence from clone RP11-338I3 on chro...	114	2e-24
emb AL353577.22  Human DNA sequence from clone RP11-661K19 on ch...	114	2e-24

>gb|AC112641.3| Homo sapiens 3 BAC RP11-431I8 (Roswell Park Cancer Institute Human BAC  
Library) complete sequence  
Length = 165619

Score = 158 bits (399), Expect = 2e-37  
Identities = 78/78 (100%), Positives = 78/78 (100%)  
Frame = +3

Query: 1 MTSPNELNKL PWTNPGETEICDLS DTEFKISVLK NLKEIQD NTEKESRILSDKYKKQIEI 60  
MTSPNELNKL PWTNPGETEICDLS DTEFKISVLK NLKEIQD NTEKESRILSDKYKKQIEI  
Sbjct: 47052 MTSPNELNKL PWTNPGETEICDLS DTEFKISVLK NLKEIQD NTEKESRILSDKYKKQIEI 47231

Query: 61 IKGNQAEI E L R N A D G T L 78  
IKGNQAEI E L R N A D G T L  
Sbjct: 47232 IKGNQAEI E L R N A D G T L 47285

23/24

Figure 17





Figure 18





## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/002641

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07K14/52

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, Sequence Search, MEDLINE, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MAHAIRAS G G ET AL: "HS 2263 B2 MR D01 CIT APPROVED HUMAN GENOMIC SPERM LIBRARY D HOMO GENOMIC CLONE PLATE=2263 COL=2 ROW=H, GENOMIC SURVEY SEQUENCE" EMBL, 21 August 1998 (1998-08-21), XP002244757 the whole document	1-42
X	KIM U-J ET AL: "CIT-HSP-510K24.TV CIT-HSP HOMO SAPIENS GENOMIC CLONE 510K24, GENOME SEQUENCE" EMBL, 14 November 1997 (1997-11-14), XP002244756 the whole document	1-42

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

23 September 2004

Date of mailing of the international search report

04/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Young, C

2

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/002641

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MUZNY D M ET AL: "Homo sapiens 3 BAC RP11-460F1 (Roswell Park Cancer Institute HUMAN BAC Library) complete Sequence" EMBL SEQUENCE DATABASE, 23 May 2000 (2000-05-23), XP002195190 the whole document	1-42
X,P	WO 03/055913 A (ARES TRADING SA ; POWER CHRISTINE (FR); PHELPS CHRISTOPHER BENJAMIN (G) 10 July 2003 (2003-07-10) the whole document	1-42

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB2004/002641

**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. type of material
- ☒ a sequence listing
- ☐ table(s) related to the sequence listing
- b. format of material
- ☒ in written format
- ☒ in computer readable form
- c. time of filing/furnishing
- ☐ contained in the international application as filed
- ☐ filed together with the international application in computer readable form
- ☒ furnished subsequently to this Authority for the purpose of search
2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2004/002641

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 17,18,20-26, 31-34 are directed to a diagnostic/therapeutic methods practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 12,14-16  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box II.1

Although claims 17,18,20-26, 31-34 are directed to a diagnostic/therapeutic methods practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

## Continuation of Box II.2

Claims Nos.: 12,14-16

Present claims 12,14-16 relate to a compounds defined by reference to a desirable characteristic or property. without reference to any structural features.

The claims cover all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). Consequently, a search can not be carried out for these claims.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/002641

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03055913	A	10-07-2003	CA 2470594 A1	03-07-2003
			CA 2470666 A1	10-07-2003
			CA 2471306 A1	10-07-2003
			WO 03054012 A2	03-07-2003
			WO 03055912 A2	10-07-2003
			WO 03055913 A2	10-07-2003
			US 2004106778 A1	03-06-2004
<hr/>				